<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>H. Programs, Schemes, Acts - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  background: url("assets/background.jpg") center center / cover no-repeat fixed;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
}

body::before {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* Responsive utilities */
@media (max-width: 768px) {
  .glass-card {
    border-radius: 16px;
  }
  
  .glass {
    border-radius: 12px;
  }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / PSM
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">63</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="flex container mx-auto px-6 gap-8">
        <!-- Question Navigation Sidebar -->
        <div class="w-80 glass p-6 h-fit sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="flex-1 max-w-4xl">
            <div class="glass-card p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <!-- Explanation Video -->
                    <div id="solutionVideo" class="hidden">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

    <script>
        let questionsData = [
  {
    "id": 2121,
    "choices": [
      {
        "id": 8473,
        "text": "<p><span style=\"font-size:12pt;\">9<sup>th</sup> five-year plan</span></p>"
      },
      {
        "id": 8474,
        "text": "<p><span style=\"font-size:12pt;\">10<sup>th</sup> five-year plan</span></p>"
      },
      {
        "id": 8475,
        "text": "<p><span style=\"font-size:12pt;\">11<sup>th</sup> five-year plan</span></p>"
      },
      {
        "id": 8476,
        "text": "<p><span style=\"font-size:12pt;\">12<sup>th</sup> five-year plan</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">In a lecture about public health initiatives correlating with economic planning, you are explaining the National Program for Prevention and Control of Fluorosis (NPPCF) to mbbs students. Understanding the significance of economic planning in public health, during which five-year plan was the NPPCF initiated in India?</span></p>",
    "unique_key": "Q9206779",
    "question_audio": null,
    "question_video": null,
    "map_id": 34335,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. 11<sup>th</sup> five-year plan</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>National Programme for Prevention and Control of Fluorosis</strong> (NPPCF) was&nbsp;a <strong>new health initiative</strong> during <strong>11th Five Year Plan</strong>, initiated in <strong>2008-09</strong> and is being <strong>expanded in a phased manner</strong>. This was <strong>launched&nbsp;by the Ministry of Health &amp; Family Welfare</strong>, <strong>Government of India</strong>.&nbsp;The <strong>objective of the program</strong> was to <strong>prevent and control fluorosis in India</strong> through various <strong>interventions</strong> like <strong>safe drinking water supply</strong>, <strong>health education</strong>, and of <strong>healthcare providers</strong> for the comprehensive management and treatment of fluorosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>National Programme for Prevention and Control of Fluorosis</strong> (NPPCF) was initiated under <strong>11th Five Year Plan in 2008.</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 561)</strong></span></p>",
    "correct_choice_id": 8475,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2233,
    "choices": [
      {
        "id": 8921,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">One HSC per 5000 population</span></span></p>"
      },
      {
        "id": 8922,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">One HSC per 3000 population</span></span></p>"
      },
      {
        "id": 8923,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">One CHC per 50000 population</span></span></p>"
      },
      {
        "id": 8924,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">One PHC per 50000 population</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When planning public health interventions for tribal areas in India, it is crucial to understand the established norms for healthcare facilities. As per the norms, which of the following is correct regarding the establishment of health centers in tribal areas?</span></span></p>",
    "unique_key": "Q1401916",
    "question_audio": null,
    "question_video": null,
    "map_id": 34336,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. One HSC per 3000 population</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">As per the <strong>present norms</strong>, <strong>tribal and hilly areas</strong> should have <strong>one Health Sub-centre</strong> (HSC) per <strong>3,000 populations</strong>, <strong>one Primary Health Centre</strong> (PHC) per <strong>20,000 populations</strong>, and a <strong>Community Health Centre</strong> (CHC) per <strong>80,000 populations</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Healthcare Infrastructure for Tribal Population -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">27&ndash;40% shortfall in Health care institutions</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">27% shortfall in Subcentres (11 states) (8% shortfall in UT Dadra and Nagar Haveli)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">40% shortfall in PHCs (7 states)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">31% shortfall in CHCs (10 states) (1 CHC shortfall in UT Dadra and Nagar Haveli)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some important Pointers related to Tribal Population -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>NTEP</strong> - Designated Microscopy Centre (DMC) - Most peripheral unit -&nbsp;Population covered: 50,000 in hilly/&nbsp;tribal areas</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>ICDS</strong> - 1 Anganwadi centre per 300&ndash;800 population in tribal projects and&nbsp;1 Mini-Anganwadi centre per 150&ndash;300 population.&nbsp;Community Development Block&nbsp;covering a population&nbsp;of 35,000 (550 villages)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Population Norms for Health Workers&nbsp;in India</strong>&nbsp;[Current Norms]<br />\r\n\tHealth Assistant (male and female) &ndash;&nbsp; 1 per 20,000 population in tribal and hilly areas<br />\r\n\tHealth Worker/Multi-purpose worker (male and female)&nbsp;&ndash;&nbsp;1 per 3,000 population in tribal and hilly areas</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">As per the <strong>present norms</strong>, <strong>tribal</strong> and <strong>hilly areas</strong> should have <strong>one Health Sub-centre</strong> (HSC) per <strong>3,000 populations</strong>, <strong>one Primary Health Centre </strong>(PHC) per <strong>20,000 populations</strong>, and a <strong>Community Health Centre</strong> (CHC) per <strong>80,000 populations.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26th edition (page 797)</strong></span></span></p>",
    "correct_choice_id": 8922,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2340,
    "choices": [
      {
        "id": 9348,
        "text": "<p><span style=\"font-size:12pt;\">30000</span></p>"
      },
      {
        "id": 9349,
        "text": "<p><span style=\"font-size:12pt;\">100000</span></p>"
      },
      {
        "id": 9350,
        "text": "<p><span style=\"font-size:12pt;\">200000</span></p>"
      },
      {
        "id": 9351,
        "text": "<p><span style=\"font-size:12pt;\">500000</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">In the plains region of a country working under the National Tuberculosis Elimination Program (NTEP), health administrators are tasked with ensuring adequate laboratory supervision for TB diagnostics. They are currently planning the deployment of Senior TB Laboratory Supervisors (STLS) to various districts. What is the maximum population coverage assigned to one Senior TB Laboratory Supervisor (STLS) in the plains for effective oversight under the National Tuberculosis Elimination Program (NTEP)?</span></p>",
    "unique_key": "Q4361437",
    "question_audio": null,
    "question_video": null,
    "map_id": 34277,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. 500000</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>RNTCP</strong> designated \u2018<strong>Microscopy Centre\u2019</strong> is established for <strong>approx. 100,000 populations</strong>&nbsp;(50,000 in hilly and mountainous areas)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Senior TB Laboratory Supervisor</strong> (STLS) is one for every <strong>5 microscopy centres</strong> -&nbsp;1 STLS per 5 lac population (2.5 lac in hilly and mountainous areas)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">STLS rechecks <strong>all +ve slides and 10% of all \u2013ve slides</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>1 STLS</strong> - on <strong>5 Microscopic centre</strong> (MC) {1 MC&nbsp;for approx. 100,000 population plains /50,000 in hilly and mountainous areas}</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 478)</strong></span></p>",
    "correct_choice_id": 9351,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 2333,
    "choices": [
      {
        "id": 9320,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">People in urban slums</span></span></p>"
      },
      {
        "id": 9321,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">People in poorly ventilated or dusty conditions</span></span></p>"
      },
      {
        "id": 9322,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">People who live in homes for elderly</span></span></p>"
      },
      {
        "id": 9323,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Work in hospital or health care professionals</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident is assigned to a public health center focusing on Tuberculosis (TB) control. Part of the task is to identify key populations who are at increased risk for TB due to their living or working conditions, as these groups require targeted interventions and screening protocols. Which of the following populations is NOT typically considered at increased risk for exposure to Tuberculosis due to their living or work environments?</span></span></p>",
    "unique_key": "Q9526423",
    "question_audio": null,
    "question_video": null,
    "map_id": 34290,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. People who live in homes for elderly</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">While <strong>elderly individuals</strong> may have an <strong>increased risk for TB</strong> due to factors like <strong>weakened immune systems</strong>, <strong>living in homes</strong> for the <strong>elderly per se</strong> is <strong>not</strong> typically considered an <strong>increased risk environment</strong> for <strong>TB exposure</strong>, in comparison to the other 3 options, which are the absolute risk factor.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Correct:</strong> <strong>People living in urban slums</strong> are at a <strong>higher risk for TB exposure</strong> due to factors such as <strong>overcrowding</strong>, <strong>poor ventilation</strong>, and limited access to healthcare services.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Correct</strong>: <strong>Working or living in poorly ventilated</strong> or dusty conditions can <strong>increase</strong> the risk of <strong>TB exposure.</strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Correct:</strong> <strong>Healthcare professionals</strong> and those working in <strong>hospitals</strong> are at an <strong>increased risk for TB exposure</strong>. They are often in close contact with patients who may have TB, especially in settings without adequate infection control measures.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">People who have <strong>Increased exposure to TB</strong> due to <strong>where they live or work:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">live in urban slums</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">live in poorly ventilated or dusty conditions</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">are contacts of TB patients, including children</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">work in environments that are overcrowded</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">work in hospitals or are health care professionals</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>People</strong> who have <strong>limited access to quality TB services</strong>:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">are from tribal populations or indigenous groups</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">are homeless</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">live in hard-to-reach areas</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">live in homes for the elderly</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">have mental or physical disabilities</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">face legal barriers to access care</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">are lesbian, gay, bisxeual or transgender.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 235)</strong></span></span></p>",
    "correct_choice_id": 9322,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 2345,
    "choices": [
      {
        "id": 9368,
        "text": "<p><span style=\"font-size:12pt;\">99 DOTS</span></p>"
      },
      {
        "id": 9369,
        "text": "<p><span style=\"font-size:12pt;\">DOTS plus</span></p>"
      },
      {
        "id": 9370,
        "text": "<p><span style=\"font-size:12pt;\">Medication Event Reminder Monitor (MERM)</span></p>"
      },
      {
        "id": 9371,
        "text": "<p><span style=\"font-size:12pt;\">Nikshay Yojana</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">In a resource-limited setting, healthcare workers are discussing innovative methods to ensure adherence to long-term treatment regimens for diseases like tuberculosis (TB). They are interested in a cost-effective, scalable solution that utilizes widely available technology to monitor patient compliance. Which of the following is a low-cost, mobile phone-based technology that allows for real-time remote monitoring of patients\u2019 daily treatment intake?</span></p>",
    "unique_key": "Q9087170",
    "question_audio": null,
    "question_video": null,
    "map_id": 34278,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. 99 DOTS</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>99DOTS</strong> (Directly Observed Treatment, Short course) is a <strong>low-cost</strong>, <strong>mobile phone-based technology</strong> that <strong>enables real-time remote monitoring</strong> of <strong>daily intake of treatment</strong>, <strong>first</strong> introduced by the <strong>Revised National Tuberculosis Programme</strong> under the <strong>national programme in 2015</strong> in <strong>high-burden antiretroviral therapy</strong> (ART) <strong>centers</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>DOTS-99: ICT-based Adherence Support</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">To <strong>ensure adherence</strong> to TB treatment, the innovative approach involves embedding hidden phone numbers in the anti-TB blister pack's custom envelope.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">This <strong>number</strong> only becomes <strong>visible when a dose is dispensed</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>After taking</strong> their <strong>daily medication</strong>, patients make a <strong>free call to this hidden number</strong>, thereby <strong>providing high confidence</strong> that the <strong>dose has been taken</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">This system <strong>allows for real-time monitoring of drug intake</strong> and ensures <strong>greater compliance</strong>. This is a <strong>low-cost approach for monitoring</strong> and <strong>improving TB medication adherence</strong>.&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"color:#000000;font-size:14px;\"><img src=\"https://lh7-us.googleusercontent.com/ay1WKXU6ti_MS3bVBiddv5ZwZLEfe2nDpThUFOfeGNsVRp9-HtbXduAv8T7_Jw5T4Xo_VDB5KdTpODBm7yZL8I-DFhIdZoJ08XUN_v85MJPR-dOhG3K6lHoYIv8lUSN7OMBw92EC2ZzqWTQYMLN5dNY\" width=\"405\" height=\"269\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B.&nbsp;DOTS plus - refers to the treatment of MDR-TB (Category IV):&nbsp;MDR/XDR treatment</strong> is started at the <strong>DOTS-plus sites</strong> where the <strong>patient is admitted for treatment for 2/3 weeks</strong>; After adjusting the medication the patient is sent back to continue his/her treatment at his respective chest clinic/DOTS provider</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.&nbsp;Medication Event Reminder Monitor (MERM)</strong>: Is&nbsp;an <strong>electronic pill box</strong> specially <strong>designed to monitor Multidrug-resistant TB</strong> (MDR-TB) <strong>treatment</strong>. Medications are dispensed in blister packs and each drug is placed in a different partitioned compartment within the pillbox<strong>.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://www.ntep.in/sites/default/files/h5p/content/1427/images/file-64358b1d59ddc.jpg\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.&nbsp;Nikshay Yojana -&nbsp;Nikshay Poshan Yojana -&nbsp;</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Financial incentive of Rs.500/-</strong> per month for <strong>each notified TB patient</strong> for <strong>duration</strong> for which the <strong>patient is on anti-TB treatment</strong>&nbsp;</span></li><li><span style=\"font-size:12pt;\">All TB patients notified on or after 1st April 2018 including&nbsp;all existing TB patients under treatment are eligible&nbsp;to receive incentives</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>DOTS 99</strong> - <strong>Low-cost</strong>, <strong>mobile phone-based technology</strong> that enables <strong>real-time remote monitoring</strong> of <strong>daily intake of treatment</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>NIKSHAY</strong>: <strong>ICT-based Surveillance Support</strong></span><br><span style=\"font-size:12pt;\">ICT enabled state-of-art surveillance system (Online monitoring software) to get notification of TB cases at diagnosis from both public and private sector including drug resistant TB patients</span></li><li><span style=\"font-size:12pt;\">Continuous monitoring and treatment adherence for all TB patients registered</span></li><li><span style=\"font-size:12pt;\">Enable tracking of all notified TB patients across TB care cycle, geographies, transfers and referrals.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: https://www.99dots.org/</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p>",
    "correct_choice_id": 9368,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 2005,
    "choices": [
      {
        "id": 8013,
        "text": "<p><span style=\"font-size:12pt;\">1960</span></p>"
      },
      {
        "id": 8014,
        "text": "<p><span style=\"font-size:12pt;\">1961</span></p>"
      },
      {
        "id": 8015,
        "text": "<p><span style=\"font-size:12pt;\">1962</span></p>"
      },
      {
        "id": 8016,
        "text": "<p><span style=\"font-size:12pt;\">1963</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">When was the Iodine deficiency disorders programme launched?</span></p>",
    "unique_key": "Q3848526",
    "question_audio": null,
    "question_video": null,
    "map_id": 34285,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. 1962</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>National Goitre Control Programme</strong> (NGCP) launched in <strong>1962</strong> (100% centrally sponsored).&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>National Iodine Deficiency Disorders Control Programme</strong> (NIDDCP) was launched in <strong>1992.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Global Iodine Deficiency Disorders</strong> (IDD) Day: <strong>21st October</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>National Goitre Control Programme</strong> (NGCP) launched - <strong>1962</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 494)</strong></span></p>",
    "correct_choice_id": 8015,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 2292,
    "choices": [
      {
        "id": 9157,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Scanty</span></span></p>"
      },
      {
        "id": 9158,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1+</span></span></p>"
      },
      {
        "id": 9159,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2+</span></span></p>"
      },
      {
        "id": 9160,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3+</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident is reviewing a sputum smear microscopy report for a patient suspected of having pulmonary tuberculosis. The report indicates the presence of acid-fast bacilli (AFB) on Ziehl-Neelsen staining. The resident must classify the smear result according to the NTEP guidelines for reporting smear microscopy results.&nbsp;The presence of 1 to 10 acid-fast bacilli (AFB) per oil immersion field on a sputum smear is classified as?</span></span></p>",
    "unique_key": "Q1897165",
    "question_audio": null,
    "question_video": null,
    "map_id": 34284,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;C. 2+</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Zeihl Neelsen</strong> (ZN) <strong>Staining</strong>&nbsp;(AFB Staining)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Sputum smear</strong> of a <strong>suspected TB patient</strong> is used for the <strong>diagnosis</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Acid Fast Bacilli</strong> (AFB) <strong>of TB</strong>: <strong>&lsquo;Rod shaped&rsquo;</strong> with <strong>&lsquo;beaded appearance&rsquo;</strong> (Beads: Mycolic Acid)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&gt;10,000 bacilli per mL sputum</strong> must be <strong>present</strong> for a <strong>positive result</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Results of ZN staining</strong>: Minimum 100 fields examined</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-162032.png\" style=\"height:215px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Grading criteria</strong> under <strong>ZN staining</strong> -&nbsp; <strong>1-10 bacilli per oil immersion field</strong> - <strong>2+ grade</strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>ZN staining Procedure</strong> - </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Fix smear on slide</strong>: Pass slide 3 times over flame (smear upside)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Carbol Fuschin cover</strong>: Steam gently for 5 minutes over direct flame</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Washing</strong>: with de-ionised water</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Decolourisation</strong>: 25% sulphuric acid</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Washing</strong>: With water</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Counter-staining</strong>: 1 minute with Loeffler&rsquo;s methylene blue</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Washing</strong>: With de-ionised water</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dry the slide</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://upload.wikimedia.org/wikipedia/commons/thumb/7/71/Mycobacterium_tuberculosis_Ziehl-Neelsen_stain_02.jpg/1280px-Mycobacterium_tuberculosis_Ziehl-Neelsen_stain_02.jpg\" style=\"height:258px; width:400px\" /></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 212)</strong></span></span></p>",
    "correct_choice_id": 9159,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 2293,
    "choices": [
      {
        "id": 9161,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1000 droplet nuclei</span></span></p>"
      },
      {
        "id": 9162,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2000 droplet nuclei</span></span></p>"
      },
      {
        "id": 9163,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3000 droplet nuclei</span></span></p>"
      },
      {
        "id": 9164,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4000 droplet nuclei</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a seminar on tuberculosis control, a question is posed to the medical residents about the transmission dynamics of Mycobacterium tuberculosis. It is emphasized that understanding the mechanisms of transmission is crucial for implementing effective infection control strategies.&nbsp;It is estimated that a single cough can generate how many droplet nuclei?</span></span></p>",
    "unique_key": "Q2137405",
    "question_audio": null,
    "question_video": null,
    "map_id": 34286,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 3000 droplet nuclei</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A <strong>cough</strong> is estimated to <strong>generate 3000 droplet nuclei</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Droplet nuclei</strong> are <strong>small respiratory droplets</strong> that may <strong>carry tubercle bacilli</strong> and can <strong>remain suspended</strong> in the <strong>air for several hours</strong>. These <strong>droplets</strong> are typically <strong>less than 5 micrometers in size</strong>, which allows them to <strong>stay airborne</strong> and <strong>potentially be inhaled</strong> by other <strong>individuals</strong>, leading to the <strong>spread of infection</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>TB bacteria remain alive</strong>: in <strong>sputum for 1 day</strong> and in <strong>droplet nuclei for 10 days</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>TB mode of transmission</strong> - Droplet infection, droplet nuclei. Droplet nuclei is a type of Indirect transmission.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A <strong>cough</strong> is estimated to <strong>generate 3000 droplet nuclei</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine, Rajvir Bhalwar (4th edition) (page 773)</strong></span></span></p>",
    "correct_choice_id": 9163,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2295,
    "choices": [
      {
        "id": 9169,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Isoniazid</span></span></p>"
      },
      {
        "id": 9170,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rifampicin</span></span></p>"
      },
      {
        "id": 9171,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pyrazinamide</span></span></p>"
      },
      {
        "id": 9172,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ethambutol</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A 25-year-old woman with a newly diagnosed case of pulmonary tuberculosis is starting her antitubercular therapy (ATT). As the treating physician, you begin to educate her about the different medications she will be taking as part of her regimen. You explain that some drugs are bactericidal, killing the actively dividing bacteria, while others are bacteriostatic, inhibiting the growth and replication of the bacteria.</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which of the following antitubercular drugs is known to be bacteriostatic?</span></span></p>",
    "unique_key": "Q2256417",
    "question_audio": null,
    "question_video": null,
    "map_id": 34287,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. Ethambutol</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ethambutol </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ethambutol is <strong>bacteriostatic</strong> and is used in <strong>combination to prevent</strong> the <strong>emergence of resistance to other drugs</strong>. It is given <strong>orally</strong>. Its <strong>major side-effect is retrobulbar neuritis</strong>; this however does not occur at the usual dosage. <strong>Ethambutol</strong> has <strong>replaced para-amino salicylic acid</strong> (PAS) almost entirely among adults.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Antitubercular Drugs</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-162411.png\" style=\"height:363px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Important Facts of Antitubercular Drugs</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most effective</strong> anti-tubercular drug: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most bactericidal</strong> antitubercular drug: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most toxic</strong> antitubercular drug: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>rapid sputum conversion</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>orange discoloration of urine</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug first to <strong>develop resistance</strong>: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug <strong>contraindicated AIDS</strong> patients on <strong>Protease Inhibitors</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug <strong>contraindicated in HIV</strong>: <strong>Thiacetazone</strong> (Exfoliative dermatitis)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drugs <strong>contained in all phases</strong> of <strong>all categories of DOTS</strong>: <strong>Rifampicin</strong> and</span></span>&nbsp;<span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Injectable</strong> Antitubercular drug: <strong>Streptomycin</strong><br />\r\n\tAntitubercular drug <strong>contraindicated in pregnancy</strong>: <strong>Streptomycin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug <strong>contraindicated in children &lt; 6 years age</strong>: <strong>Ethambutol</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>Optic neuritis</strong> (Red-Green color blindness): <strong>Ethambutol</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing vestibular damage: Streptomycin</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Only Bacteriostatic drug in Primary ATT Drugs - Ethambutol</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 215)</strong></span></span></p>",
    "correct_choice_id": 9172,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2297,
    "choices": [
      {
        "id": 9177,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Carried out by injecting 1 TU of PPD in 0.1 ml intradermally on the flexor surface of the left forearm</span></span></p>"
      },
      {
        "id": 9178,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Result of the test is read after 48-96 hours but 72 hours (3rd day) is the ideal.</span></span></p>"
      },
      {
        "id": 9179,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">For HIV positive persons 2 mm induration is significant</span></span></p>"
      },
      {
        "id": 9180,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">For persons with no risk factors for tuberculosis 15 mm is significant</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident is conducting a seminar on tuberculosis (TB) screening methods. One topic of discussion is the use of the tuberculin skin test (TST), which is commonly used in the identification of TB infection. The resident is aware that while the TST is a valuable tool in TB control, it has certain characteristics and limitations that must be understood for proper interpretation and application. Which of the following statements is NOT true regarding the tuberculin skin test (TST)?</span></span></p>",
    "unique_key": "Q1430804",
    "question_audio": null,
    "question_video": null,
    "map_id": 34288,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. For HIV positive persons 2 mm induration is significant</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>Tuberculin Skin Test</strong> (TST) is used to <strong>detect exposure to tuberculosis</strong>. In <strong>HIV positive individuals</strong>, the <strong>immune response</strong> may be <strong>diminished</strong> due to the <strong>compromised immune system</strong>. Therefore, a <strong>smaller induration</strong> (5 mm, not 2 mm) is considered significant in <strong>HIV positive patients</strong>, as well as in <strong>recent contacts of active TB cases</strong>, persons with <strong>fibrotic changes on chest radiographs</strong> consistent with <strong>prior TB</strong>, and patients with <strong>organ transplants</strong> and other <strong>immunosuppressed patients</strong>. </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation: </u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Correct: </strong>The <strong>TST</strong> is <strong>indeed administered by injecting 1 TU</strong> (Tuberculin Unit) of <strong>purified protein derivative</strong> (PPD) <strong>intradermally</strong> on the forearm. This is the standard method of administration<strong>.</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Correct: </strong>The results of the <strong>TST</strong> are typically <strong>read between 48-96 hours</strong> <strong>after administration</strong>, with 72 hours being the ideal time frame for reading the result.</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Correct: </strong>In <strong>individuals</strong> with <strong>no known risk factors for tuberculosis</strong>, a <strong>larger induration</strong> (&ge;15 mm) is necessary to be considered significant. This is because the likelihood of TB exposure or latent infection is lower in this group.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin Test</strong> and <strong>Mantoux Test</strong> (Pirquet test or PPD Test) are the tool for <strong>detecting TB infection</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin/PPD</strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin</strong>: <strong>Purified protein derivative</strong> (PPD) has <strong>replaced</strong> the <strong>antigen old tuberculin</strong> (OT).&nbsp;Tuberculins have also been prepared from atypical mycobacterium: PPD-Y (M. Kansasii), PPD-B (Battey mycobacterium), Scrofula (M. scrofulaceum)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Discovered by <strong>Von Pirquet</strong> (1907)</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Standard PPD</strong> (PPD-S) <strong>contains</strong> -&nbsp;50,000 tuberculin units (TU) per mg [1TU= 0.00002 mg PPD]</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">WHO advocates <strong>&rsquo;PPD-RT-23 with Tween-80&rsquo;</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dosage</strong>: First strength (1TU), Intermediate strength (5TU), Second strength (250TU)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin test conversion</strong> is defined as an <strong>increase of 10 mm </strong>or <strong>more within a 2-year period</strong>, regardless of age</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin test in use</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mantoux intradermal test: More precise test of tuberculin sensitivity</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Heaf test: Quick, easy, reliable and cheap, preferred for testing large groups</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tine multiple puncture test unreliable, not recommended</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin test</strong> is the <strong>&lsquo;only way of estimating</strong> the <strong>prevalence of infection</strong> in a <strong>population&rsquo;</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tuberculin test has lost its sensitivity as an indicator of the true prevalence of infection, in countries with high coverage of BCG &ndash; True prevalence rates are exaggerated by infection with atypical mycobacteria and boosting effect of a second dose of tuberculin</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mantoux Test</strong> (Tool for detection of TB infection) (Pirquet Test)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img alt=\"Tuberculin Skin Test (Positive Mantoux Test) Result, Reading and  Interpretation - Jotscroll | Mantoux test, Tb test, Medical assistant  student\" src=\"https://i.pinimg.com/474x/cd/b4/a4/cdb4a48dd959cbea9ac399486b7b48a1.jpg\" style=\"height:249px; width:400px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin test conversion</strong>: Increase of &gt; 10 mm within 2 years period</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dose</strong>: 1 TU of PPD in 0.1ml injected intradermally on forearm</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">WHO advocated preparation: PPD&ndash;RT&ndash;23 with Tween&ndash;80</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Is a test of prognostic significance</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Has limited validity due to lack of specificity</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Readings: Result read after 72 hrs (3d)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Only induration is measured:</span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Induration &gt;9 mm: Positive (Past OR current infection with TB)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Induration 6-9 mm: Doubtful (M. tuberculosis or Atypical mycobacteria)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Induration &lt;6 mm: Negative</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Results of tuberculin test must be interpreted carefully</strong>: The person&rsquo;s medical risk factors determine at which increment (5 mm, 10 mm, or 15 mm) of induration the result is considered positive</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>5 mm or more is positive in</strong>:&nbsp;</span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">HIV-positive person</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Recent contacts of TB case</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Persons with nodular or fibrotic changes on chest X-ray consistent with old healed TB&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patients with organ transplants</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Other immunosuppressed patients</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>10 mm or more is positive in:</strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Recent arrivals (less than 5 years) from high-prevalence countries</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Injection drug users</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes,hospitals, homeless shelters, etc.)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mycobacteriology lab personnel</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Persons with clinical conditions that place them at high risk (diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes,low body weight)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children less than 4 years of age, or children and adolescents exposed to adults in high-risk categories</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>15 mm or more is positive in:</strong>&nbsp;Persons with <strong>no known risk factors for TB</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 213)</strong></span></span></p>",
    "correct_choice_id": 9179,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 2300,
    "choices": [
      {
        "id": 9189,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MDR TB with resistance to fluoroquinolones</span></span></p>"
      },
      {
        "id": 9190,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">XDR TB</span></span></p>"
      },
      {
        "id": 9191,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mixed pattern resistant TB</span></span></p>"
      },
      {
        "id": 9192,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Treatment failure of drug sensitive TB</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A pulmonologist is reviewing the eligibility criteria for the addition of Bedaquiline to the treatment regimen of patients with tuberculosis. Bedaquiline, a newer medication, is used in specific scenarios and patient populations based on the national guidelines to improve treatment outcomes while considering the risk of side effects.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which of the following patients with tuberculosis is NOT typically eligible for Bedaquiline therapy according to standard tuberculosis management guidelines?</span></span></p>",
    "unique_key": "Q8281251",
    "question_audio": null,
    "question_video": null,
    "map_id": 34289,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;D. Treatment failure of drug sensitive TB</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Bedaquiline</strong> is a <strong>newer medication</strong> that has been introduced for the <strong>treatment of multidrug-resistant tuberculosis</strong> (MDR-TB). Its use is generally recommended in cases where the <strong>TB strain is resistant to conventional first-line drugs</strong>. Therefore, a <strong>patient</strong> experiencing <strong>treatment failure with drug-sensitive TB</strong> (i.e., TB that responds to standard first-line anti-TB drugs) would <strong>not</strong> typically be a <strong>candidate for Bedaquiline therapy</strong>. This drug is <strong>reserved for more complex cases</strong> where the <strong>TB strain is resistant</strong> to <strong>standard treatment</strong>, not for cases where the standard treatment has failed due to other reasons like poor adherence or suboptimal drug levels.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The following group of <strong>patients are eligible for BDQ therapy</strong>:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MDR/RR TB with resistance to any/all fluoroquinolones (FQ) or to any/all second-line injectable agents (SLI) <strong>(Option A)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">XDR-TB <strong>(Option B)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mixed pattern resistant TB (XDR-TB + additional first line I second line resistant TB) <strong>(Option C)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Treatment failure of MDR-TB + FQ/SLI resistance or XDR-TB</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>New Anti-Tubercular Drugs</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Two</strong> new drugs named <strong>Bedaquiline</strong> and <strong>Delamanid</strong> with <strong>anti-TB effect</strong> were approved for <strong>treatment of multidrug resistant TB</strong> by The <strong>Central Drugs Standard Control Organization</strong> (CDSCO)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Bedaquiline</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Introduction: <strong>Diarylquinoline drug</strong> which targets <strong>Mycobacterial ATP synthase</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Extended half-life: Present even 5.5 months after stoppage</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Significant use in culture-conversion time for MDR-TB</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patient selection criteria: Age 18 years or more with MDR-TB</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Contraindications: Pregnancy, Cardiac arrhythmia</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dosage&nbsp;</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Week 0&ndash;2&nbsp;- BDQ 400 mg daily + OBR (Optimized background regimen)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Week 3&ndash;24 - BDQ 200 mg thrice a week + OBR (Optimized background regimen)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Week 25 - End Continue other 2nd line drugs as per RNTCP</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Delamanid</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">DCG India allow 50 mg usage as Combination regimen for Pulmonary MDT-TB.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Bedaquiline</strong> and <strong>Delamanid</strong> with <strong>anti-TB effect</strong> were approved for <strong>treatment of multidrug resistant TB</strong> by The <strong>Central Drugs Standard Control Organization</strong> (CDSCO).&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Bedaquiline</strong> is reserved for use in cases of <strong>MDR-TB and XDR-TB</strong>, where first-line treatments are either not effective or not tolerated.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 215)</strong></span></span></p>",
    "correct_choice_id": 9192,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2304,
    "choices": [
      {
        "id": 9205,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3</span></span></p>"
      },
      {
        "id": 9206,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4</span></span></p>"
      },
      {
        "id": 9207,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5</span></span></p>"
      },
      {
        "id": 9208,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">6</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In the outpatient clinic, a resident physician is tasked with prescribing anti-tuberculosis therapy for an adult patient diagnosed with pulmonary tuberculosis. The patient&rsquo;s weight is 60 kg, and as per the latest protocols, Fixed-Dose Combinations (FDCs) are to be used to simplify the regimen and improve adherence.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">How many tablets of the Fixed-Dose Combination (FDC) regimen should be given to a patient weighing between 50 to 64 kg according to the National Tuberculosis Elimination Programme (NTEP)?</span></span></p>",
    "unique_key": "Q4195707",
    "question_audio": null,
    "question_video": null,
    "map_id": 34275,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. 4</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment Protocol</strong>: <strong>NEW Guidelines</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patients are given <strong>fixed drug combinations</strong> (FDCs), on a <strong>Daily basis</strong> (1 November 2017 onwards PAN-India)</span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduced pill burden: 3&ndash;4 drugs in a single pill (as against 7 tablets earlier)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Lesser relapses</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduction in drug-resistance</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Greater compliance</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Paediatric patients</strong> are given <strong>easily-dissolvable</strong> and <strong>flavored drugs</strong> (instead of bitter tablets earlier)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Weight bands</strong>: Patients get appropriate dosages as per body weight</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>TB-HIV Coinfection</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&lsquo;Intensified TB case finding and appropriate treatment&rsquo; through single window delivery of services from all ART centres</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">INH preventive therapy for prevention of TB among PLHIV</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Implementation of Pharmacovigilance by establishing adverse drug reaction monitoring centres at ART centres</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Patients not registered under DOTS</strong> are <strong>provided Intermittent</strong> (alternate day OR Thrice weekly) regimen.</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment of TB</strong> under <strong>NTEP</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment Regimen</strong> for <strong>Drug-Sensitive TB</strong> (DSTB) <strong>New</strong> and <strong>previously treated cases</strong>:&nbsp;<strong>2 HRZE</strong> (IP 56 doses) + <strong>4HRE</strong> (CP 112 doses)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fixed Dose Combinations (FDCs): Products containing two or more active ingredients in fixed doses, used for a particular indication(s)</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Adults: 4-FDC (IP &ndash; HRZE) and 3-FDC (CP &ndash; HRE)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Paediatric patients: Dispersible 3-FDC (HRZ) and Dispersible 2-FDC (HR)</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. Weight Bands Based Treatment</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Weight bands Adults - FIVE</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-114650.png\" style=\"height:276px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Weight bands Paediatrics - SIX</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-114710.png\" style=\"height:261px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2. Long term Follow-up -&nbsp; After completion of treatment, the patients should be followed up clinically at the end of 6, 12,18 &amp; 24 months.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><strong>Reference: Park 26<sup>th</sup> edition (page 218)</strong></span></span></p>",
    "correct_choice_id": 9206,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 2306,
    "choices": [
      {
        "id": 9213,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Nikshay</span></span></p>"
      },
      {
        "id": 9214,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Nitchay</span></span></p>"
      },
      {
        "id": 9215,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">End TB portal</span></span></p>"
      },
      {
        "id": 9216,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">TB mukt bharat</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">During a departmental meeting at a local health clinic, a discussion is held regarding the digitization of health records for better monitoring and follow-up of patients with tuberculosis (TB). A new medical officer who recently joined the clinic is learning about the various protocols and systems in place as per the National Tuberculosis Elimination Programme (NTEP).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which portal is utilized for the entry and management of treatment details of patients with tuberculosis, as mandated by the National Tuberculosis Elimination Programme?</span></span></p>",
    "unique_key": "Q4848681",
    "question_audio": null,
    "question_video": null,
    "map_id": 34276,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Nikshay</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>NIKSHAY: ICT-based Surveillance Support</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/09/image-20231109192341-1.png\" style=\"height:142px; width:354px\" /></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>ICT enabled state-of-art surveillance system</strong> (Online monitoring software) to get <strong>notification of TB cases</strong> at diagnosis from <strong>both public</strong> and <strong>private sector</strong> including <strong>drug-resistant TB patients</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Continuous monitoring</strong> and <strong>treatment adherence</strong> for all <strong>TB patients registered</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Enable tracking of all notified TB patients</strong> across <strong>TB care cycle, geographies, transfers</strong> and <strong>referrals</strong>.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NIKSHAY FLOW</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Nikshay Entry: Once the treatment regimen is finalized, all patients will be initiated on treatment after opening of the treatment card and entries are done in Nikshay</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patient flow in Nikshay:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay 1</strong>: Initiating the patient on appropriate treatment regimen</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay 2:</strong> Transfer / referral flow after initiation of treatment</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay 3:</strong> Nikshay Aushadhi</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>NIKSHAY MITRA INITIATIVE</strong> (NMI)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>NMI</strong> is a part of <strong>Pradhan Mantri TB Mukt Bharat Abhiyaan</strong> launched by The <strong>President of India</strong> on September 9, 2022</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay Mitra</strong> is a <strong>government project</strong> that enables people to <strong>adopt tuberculosis patients</strong> and take care of their nutritional and medical requirement, with an aim to combat stigma associated with the disease</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay Mitra</strong> has a <strong>number of choices</strong> for help, including <strong>dietary, diagnostic, occupational</strong>, and <strong>supplementary nutritional supplements</strong>. In addition, they can select a support period of one to three years. They can select the state, district, building, and medical facilities. The district TB officer will make it easier to become Nikshay Mitra.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Objectives of the Initiative</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Provide additional patient support to improve treatment outcomes of TB patients</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Augment community involvement in meeting India&rsquo;s commitment to end TB by 2025</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Leverage Corporate Social Responsibility (CSR) activities</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Additional assistance</strong> that may be provided by the<strong> Nikshay Mitra to on-treatment TB patients</strong>: Nutritional support, Additional investigations for the diagnosed TB patients, Vocational support, Additional nutritional supplements</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some important Pointers about NTEP -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay Poshan Yojana:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Financial incentive of Rs 500/- per month</strong> for each notified TB patient for duration for which the patient is on anti-TB treatment</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">All <strong>TB patients notified on or after 1st April 2018</strong> including all existing TB patients under treatment are eligible to receive incentive</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">All TB patients who have been diagnosed and registered under NTEP will be referred for screening for Diabetes</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Two new drugs named Bedaquiline and Delamanid with anti-TB effect were approved for treatment of multidrug resistant TB by The Central Drugs Standard Control Organization (CDSCO)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 218)</strong></span></span></p>",
    "correct_choice_id": 9213,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2316,
    "choices": [
      {
        "id": 9253,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chest X ray</span></span></p>"
      },
      {
        "id": 9254,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tuberculin skin test</span></span></p>"
      },
      {
        "id": 9255,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Gastric aspirate</span></span></p>"
      },
      {
        "id": 9256,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Serological tests</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A 5-year-old boy presents to a rural health clinic with a persistent cough, fever, and weight loss. His history reveals contact with an uncle who was recently diagnosed with pulmonary tuberculosis. The child is too young to produce a reliable sputum sample for direct acid-fast bacilli (AFB) testing, and the healthcare team must consider alternative diagnostic methods as per the National Tuberculosis Elimination Programme (NTEP) guidelines for pediatric tuberculosis cases.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which of the following diagnostic methods is NOT recommended for detecting tuberculosis in children who cannot provide a sputum sample, according to NTEP guidelines?</span></span></p>",
    "unique_key": "Q2874780",
    "question_audio": null,
    "question_video": null,
    "map_id": 34279,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;D. Serological tests</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Serological tests</strong> are <strong>Banned in India</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In situations where <strong>M. tuberculosis</strong> is <strong>not detected</strong> or a <strong>specimen is not available</strong>, <strong>chest X-ray</strong> (option A) and <strong>Tuberculin skin test</strong> (TST) (Option B) by Mantoux technique using 2 TU of PPD RT 23 should be done. <strong>Gastric aspirate</strong> (Option C) can be used.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Diagnosis of TB under NTEP/ RNTCP</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. <strong>Microscopy:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">ZN staining-based Conventional Microscopy (First main test performed)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Light Emitting Diode-based Fluorescence Microscopy (LED FM)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2. <strong>Culture</strong> (Diagnosis):</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Solid Lowenstein Jensen (LJ) Medium</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Automated Liquid Culture Systems (BACTEC MGIT 960, Bactialert, VersaTrek)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3. <strong>Culture</strong> (Drug Sensitivity Testing):</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Modified PST for MGIT 960 system (for both 1st and 2nd line drugs)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Proportional Sensitivity Testing (1%) Economic variant using LJ Medium (as back-up)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4. <strong>Rapid Molecular Diagnostic Testing:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Line Probe Assay (MTB complex and INH/RIF resistance)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cartridge based nucleic acid amplification test (CBNAAT&ndash;Xpert/MTB/Rif testing using GeneXpert system)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5. <strong>Other Diagnostic Tests</strong>:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chest X-ray (Mainly for screening. If used for diagnosis its known as Clinically diagnosed TB)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Standardized Tuberculin Skin Test (Complimentary test in children)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Interferon Gamma Release Assay (IGRA&ndash;Not recommended for adults in India)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Serological tests (Banned in India).</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 224)</strong></span></span></p>",
    "correct_choice_id": 9256,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2317,
    "choices": [
      {
        "id": 9257,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">10 mg/kg daily for 6 months</span></span></p>"
      },
      {
        "id": 9258,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 mg/kg daily for 6 months</span></span></p>"
      },
      {
        "id": 9259,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">10 mg/kg daily for 12 months</span></span></p>"
      },
      {
        "id": 9260,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 mg/kg daily for 12 months</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a public health internship, a medical resident is tasked with finding the updated recent protocol for tuberculosis (TB) contact tracing and prophylaxis. One key component of the protocol involves the administration of isoniazid as a chemoprophylactic agent to prevent the development of active TB in individuals who have been in close contact with TB patients. What is the recommended dose of isoniazid for chemoprophylaxis in individuals who have been identified as close contacts of patients with tuberculosis?</span></span></p>",
    "unique_key": "Q3333427",
    "question_audio": null,
    "question_video": null,
    "map_id": 34280,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. 10 mg/kg daily for 6 months</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>dose of INH</strong> for <strong>chemoprophylaxis is 10 mg/kg</strong> (instead of 5 mg/kg) administered daily for <strong>6 months</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>INH Preventive Therapy</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. <strong>INH Preventive Therapy in Children</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Children &lt;6 years of age</strong> in <strong>close contact</strong> (But TB excluded)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">HIV infected children who either had a known <strong>exposure to an infectious TB case</strong> or are</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin skin test</strong> (TST) <strong>positive</strong> (&gt;=5mm induration) but have no active TB disease</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">All <strong>TST positive children</strong> who are receiving <strong>immunosuppressive therapy</strong> (e.g. Children with nephrotic syndrome, acute leukaemia, etc.)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A child born to mother who was diagnosed to have TB in pregnancy provided congenital TB has been ruled out</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2. <strong>INH Preventive Therapy in Adults</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adults</strong> and <strong>adolescents</strong> living with <strong>HIV</strong> <strong>unlikely</strong> to have <strong>active TB</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children living with HIV who do not have poor weight gain, fever or current cough unlikely to have active TB</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children living with HIV if evaluation shows no TB</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3<strong>. Dose of IPT Used under NTEP -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Adult and Adolescent: Isoniazid 300 mg + Pyridoxine 50 mg per day &times; 6 months</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children above 12 months: Isoniazid 10 mg/kg + Pyridoxine 25 mg per day &times; 6 months</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Important Pointers: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Antitubercular drugs</strong> contained in <strong>all phases of all categories of DOTS</strong>: <strong>Rifampicin </strong>and <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most <strong>effective drug</strong> out of <strong>HRZES - H and R</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Antitubercular drug</strong> first to develop resistance: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most toxic antitubercular drug: Isoniazid</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Multidrug Resistant TB (MDR&ndash;TB): Resistance to Isoniazid and Rifampicin &lsquo;with or without resistance to other drugs&rsquo;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Extensive Drug Resistant TB (XDR&ndash;TB): Resistance to rifampicin and isoniazid AND to any member of the quinolone family AND to one of the injectable second-line drugs (kanamycin, capreomycin, or amikacin)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">XDR&ndash;TB is MDR TB with further resistance to 3 &ndash; 6 classes of second line drugs (Older definition)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dose of IPT Used under NTEP</strong> -&nbsp;&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adult and Adolescent</strong>: Isoniazid 300 mg + Pyridoxine 50 mg per day &times; 6 months</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Children above 12 months</strong>: Isoniazid 10 mg/kg + Pyridoxine 25 mg per day &times; 6 months</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 225)</strong></span></span></p>",
    "correct_choice_id": 9257,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 2318,
    "choices": [
      {
        "id": 9261,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Isoniazid</span></span></p>"
      },
      {
        "id": 9262,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rifampicin</span></span></p>"
      },
      {
        "id": 9263,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pyrazinamide</span></span></p>"
      },
      {
        "id": 92699,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Streptomycin</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 27-year-old woman who is 16 weeks pregnant presents to the clinic with a cough, night sweats, and a weight loss of 10 pounds over the last two months. A sputum sample is positive for acid-fast bacilli, and a chest X-ray is consistent with active pulmonary tuberculosis (TB). The patient is HIV negative. Her obstetrician must now collaborate with an infectious disease specialist to determine an appropriate treatment regimen that is safe for both the mother and the fetus. Which of the following anti-tuberculous medications is CONTRAINDICATED in this pregnant patient?</span></span></p>",
    "unique_key": "Q4418911",
    "question_audio": null,
    "question_video": null,
    "map_id": 34281,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Streptomycin</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Before initiating treatment</strong> for <strong>tuberculosis</strong>, <strong>women of childbearing age</strong> should be asked about <strong>current or planned pregnancy</strong> and <strong>counselled appropriately</strong>. A <strong>successful treatment of TB</strong> is important for <strong>successful outcome of pregnancy</strong>. With the exception of streptomycin, the <strong>first line anti-TB drugs</strong> are <strong>safe for use in pregnancy</strong>. <strong>Streptomycin</strong> is <strong>oto-toxic</strong> to the <strong>foetus</strong> and should not be used during pregnancy.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Other 3 options (Isoniazid, Rifampicin and Pyrazinamide) are safe to use in pregnancy&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Important Facts of Antitubercular Drugs</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most effective</strong> anti-tubercular drug: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most bactericidal</strong> antitubercular drug: <strong>Rifampicin</strong> </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most toxic</strong> antitubercular drug: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>rapid sputum conversion</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>orange discoloration of urine</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug <strong>first to develop resistance</strong>: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug contraindicated AIDS patients on Protease Inhibitors: Rifampicin</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug contraindicated in HIV: Thiacetazone (Exfoliative dermatitis)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drugs contained in all phases of all categories of DOTS: Rifampicin and Isoniazid</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Injectable Antitubercular drug: Streptomycin</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug contraindicated in children &lt; 6 years age: Ethambutol</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing Optic neuritis (Red-Green color blindness): Ethambutol</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing vestibular damage: Streptomycin</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug contraindicated in pregnancy: Streptomycin</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 225)</strong></span></span></p>",
    "correct_choice_id": 92699,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2320,
    "choices": [
      {
        "id": 9268,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Jeryl Lynn strain is used for production of BCG vaccine</span></span></p>"
      },
      {
        "id": 9269,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">For vaccination, the usual strength is 0.1 mg in 0.1 ml volume</span></span></p>"
      },
      {
        "id": 9270,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The site of injection should be just above the insertion of the left deltoid muscle</span></span></p>"
      },
      {
        "id": 9271,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The duration of protection is from 15 to 20 years.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a primary care clinic, a group of nursing students is being taught about the Bacille Calmette-Gu&eacute;rin (BCG) vaccine, its administration, and its role in tuberculosis prevention. The discussion covers various aspects of the vaccine, including production, dosage, administration, and duration of protection. Which of the following statements regarding the BCG vaccine is NOT accurate?</span></span></p>",
    "unique_key": "Q1110687",
    "question_audio": null,
    "question_video": null,
    "map_id": 34283,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Jeryl Lynn strain is used for production of BCG vaccine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>Jeryl Lynn strain</strong> is used for the <strong>production of the mumps vaccine</strong>, not the BCG vaccine<strong><em>.</em></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The WHO has recommended the &quot;<strong>Danish 1331&rdquo; strain</strong> for the <strong>production of BCG vaccine</strong>. The <strong>vaccine strain</strong> is derived from <strong>Mycobacterium bovis</strong>. Since January 1967, the BCG Laboratory at Guindy, Chennai, has been using the &ldquo;Danish 1331&rdquo; strain for the production of BCG vaccine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>BCG Vaccine -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>BCG stands for &lsquo;Bacille Calmette Guerin&rsquo;</strong> &ndash; an &lsquo;avirulent strain&rsquo; produced by 239 subcultures over a period of 13 years</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Live attenuated vaccine</strong> &ndash; Freeze dried (lyophilized) vaccine: More stable; used currently</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>BCG is&nbsp;reconstituted with Normal Saline</strong> (NaCl) <strong>as diluent</strong>&nbsp;&ndash; Must be used within 4 hours of reconstitution</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dose: 0.1 mL</strong> (for all ages);&nbsp;Strength: 0.1 mg in 0.1 mL</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Route: Intra-dermal</strong>&nbsp;&ndash; Tuberculin syringe (Omega microstat syringe, 1 cm steel,26-gauge needle)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Site: Skin over left deltoid muscle</strong>&nbsp;&ndash; Left deltoid muscle is chosen ONLY by convention</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Correct: </strong>The typical dosage for the BCG vaccine is 0.1 mg in a 0.1 ml volume. This is a standard concentration used in the administration of the vaccine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Correct</strong>: The recommended site of injection for the BCG vaccine is intradermally just above the insertion of the deltoid muscle, often on the left arm. This is a common practice for ease of administration and monitoring of the site.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Correct: </strong>The duration of protection provided by the BCG vaccine is generally estimated to be between 15 to 20 years. This duration can vary based on individual immune response and other factors.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Strains of Commonly Used Vaccines</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>BCG - Danish-1331 strain</strong> (WHO recommended)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">OPV/IPV - P1, P2, P3 strains (Monovalent or Trivalent or Bivalent)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles vaccine</strong> - Edmonston Zagreb strain (MC);&nbsp;Schwartz strain;&nbsp;Moraten strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mumps vaccine</strong> - Jeryll Lynn strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rubella vaccine</strong> - RA 27/3</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Yellow Fever vaccine</strong> - 17 D strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Varicella vaccine</strong> - OKA strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Japanese Encephalitis vaccine</strong> - Nakayama strain;&nbsp;Beijing P3 strain;&nbsp;SA 14-14-2 (Used in India)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Swine Flu Vaccine</strong> (killed) - A7/California/2009</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Malaria vaccine SPf </strong>- 66 strain (Lytic Coktail);&nbsp;Pf 25 strain;&nbsp;RTS, S/AS01 (Mosquirix)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">HIV vaccines - mVA (modified Vaccinia Ankara) strain;&nbsp;rAAV (recombinant Adeno associated viral vaccine) strain;&nbsp;CTL&nbsp;(Cytotoxic T-lymphocytic) strain;&nbsp;AIDSVAX strain;&nbsp;Subunit Vaccine strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Typhoral vaccine - Ty 21 a</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Covaxin - Niv-2020-770</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 226)</strong></span></span></p>",
    "correct_choice_id": 9268,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 2350,
    "choices": [
      {
        "id": 9388,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">0% having catastrophic expenditure due to TB</span></span></p>"
      },
      {
        "id": 9389,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">70% increase in case finding</span></span></p>"
      },
      {
        "id": 9390,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">80% reduction in TB incidence</span></span></p>"
      },
      {
        "id": 9391,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">90% reduction in TB mortality</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A group of public health professionals is evaluating the country&rsquo;s progress toward the targets set by the National Strategic Plan for Tuberculosis (TB) elimination. In the course of their review, they compare the set objectives against the milestones reached and strategize on how to address the gaps. Which of the following is NOT an objective within the National Strategic Plan to achieve the elimination of tuberculosis by 2025?</span></span></p>",
    "unique_key": "Q9391992",
    "question_audio": null,
    "question_video": null,
    "map_id": 34282,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans.&nbsp;B. 70% increase in case finding</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>National Strategic Plan</strong> aims to achieve the <strong>elimination of TB by 2025</strong>. </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Under SDGs</strong>&ndash;Specific <strong>Targets for SDG Target 3.3 on Infectious Diseases</strong> -&nbsp;Targets for TB are:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. 0% patient</strong> having <strong>catastrophic expenditure</strong> due to TB</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. 80% reduction</strong> in <strong>TB incidence</strong> (i.e. reduction from 211 per lakh to 43 per lakh)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. 90% reduction</strong> in <strong>TB mortality</strong> (i.e. reduction from 32 per lakh to 3 per lakh)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Timeline of TB Programs in India</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1962:</strong> National TB Control Program (NTP) launched [Strategy: BCG vaccination, TB treatment]</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1992-93</strong>: Revised National TB Control Program (RNTCP) launched [Strategy: DOTS]</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>01 January 2020</strong>: National TB Elimination Program (NTEP) launched</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>SDG target</strong> (3.3) for <strong>Ending the epidemic of TB</strong> are <strong>90% reduction in TB deaths</strong>;<strong>&nbsp;80% reduction</strong> in <strong>TB incidence rate</strong> and&nbsp;<strong>Zero TB-affected families</strong> facing <strong>catastrophic costs</strong> due to TB</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>National Strategic Plan (NSP) - TB 2017-25</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>VISION</strong>: TB-Free India with zero deaths, disease and poverty due to TB</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>GOAL:</strong> To achieve a rapid decline in burden of TB, morbidity and mortality while working towards elimination of TB in India by 2025</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NSP sets out the strategic direction and key initiatives that the MoHFW will undertake from 2017-25 for working towards achieving the goals of eliminating TB by 2025 (Achieve SDG and End TB targets for India)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Approach: <strong>&lsquo;DETECT-TREAT-PREVENT-BUILD&rsquo; approach</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Strategic Focus Areas</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Early diagnosis of all the TB patients</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Prompt treatment with the right drugs and regimens</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patient financial and nutritional support</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Active case finding</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Contact tracing</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">LTBI management in high risk population</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Airborne infection control</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 483)</strong></span></span></p>",
    "correct_choice_id": 9389,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2007,
    "choices": [
      {
        "id": 8021,
        "text": "<p><span style=\"font-size:12pt;\">Vitamin A prophylaxis programme</span></p>"
      },
      {
        "id": 8022,
        "text": "<p><span style=\"font-size:12pt;\">Anaemia Mukt Bharat</span></p>"
      },
      {
        "id": 8023,
        "text": "<p><span style=\"font-size:12pt;\">National Iodine deficiency disorder control programme</span></p>"
      },
      {
        "id": 8024,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Mid-day meal programme</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">While attending a public health seminar, a medical student views several logos related to various nutritional programs in India. One of the logos is meant to represent a program that addresses the widespread issue in India. Which nutritional program in India is associated with this logo?</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture44.jpg\" width=\"400\" height=\"372\"></p>",
    "unique_key": "Q9487027",
    "question_audio": null,
    "question_video": null,
    "map_id": 34294,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. National Iodine deficiency disorder control programme</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>NIDDCP</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>National Goitre Control Programme</strong> (NGCP) launched in <strong>1962</strong> (100% centrally sponsored)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>National Iodine Deficiency Disorders Control Programme</strong> (NIDDCP) was launched in <strong>1992</strong>.</span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://4.bp.blogspot.com/-8lR48LR1Hg8/WUFz0MhBhuI/AAAAAAAABWA/K0HAayBzQ3wHlOaTDlVCdBrgCjLAHaYMACLcBGAs/s640/Namak.jpg\" alt=\"81 \u0939\u091c\u093e\u0930 \u0915\u094d\u0935\u093f\u0902\u091f\u0932 \u0932\u0947 \u091c\u093e\u0926\u093e \u0906\u092f\u094b\u0921\u0940\u0928 \u0928\u092e\u0915 \u0906\u0935\u0902\u091f\u093f\u0924\" width=\"400\" height=\"267\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>important objectives</strong> and <strong>components of National Iodine Deficiency Disorders Control Iodine Deficiency Disorders Control Programme</strong> (NIDDCP) are as follows: -</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Surveys</strong> to <strong>assess the magnitude</strong> of the <strong>Iodine Deficiency Disorders</strong>.</span></li><li><span style=\"font-size:12pt;\"><strong>Supply</strong> of <strong>iodized salt</strong> in place of common salt.</span></li><li><span style=\"font-size:12pt;\"><strong>Resurvey</strong> after <strong>every 5 years</strong> to <strong>assess the extent of Iodine Deficiency Disorders</strong> and the impact of iodized salt.</span></li><li><span style=\"font-size:12pt;\"><strong>Laboratory monitoring</strong> of <strong>iodized salt</strong> and urinary iodine excretion.</span></li><li><span style=\"font-size:12pt;\">Health education &amp; Publicity.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.&nbsp;Vitamin A prophylaxis programme - No specific logo. The logo is for NPCBVI -&nbsp;</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://npcbvi.mohfw.gov.in/Image/logo1.png\" alt=\"NPCBVI\" width=\"400\" height=\"400\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. Anemia Mukt Bharat -&nbsp;</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://play-lh.googleusercontent.com/MVUfnbDvILIBylE0P851UfBI-s7hvzRIpzW4I2nASfOG8L74GFRwOUSKb17WpKEynt4\" alt=\"Anemia Mukt Bharat - Apps on Google Play\" width=\"400\" height=\"400\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Mid-day meal Program&nbsp;</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://w7.pngwing.com/pngs/697/822/png-transparent-midday-meal-scheme-school-government-of-india-primary-education-school-education-text-class-nutrition.png\" alt=\"Midday Meal Scheme png images | PNGWing\" width=\"400\" height=\"434\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Indicators</strong> to <strong>Monitor Success of NIDDCP</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Process Indicators</strong>: Indicators to <strong>monitor and evaluate</strong> the <strong>salt iodization process</strong></span><ul><li><span style=\"font-size:12pt;\">Salt iodine content at the production site</span></li><li><span style=\"font-size:12pt;\">Salt iodine content at point of packaging</span></li><li><span style=\"font-size:12pt;\">Salt iodine content at wholesale and retail levels</span></li><li><span style=\"font-size:12pt;\">Salt iodine content in households</span></li></ul></li></ul><p style=\"margin-left:24px;\">&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Impact Indicators</strong>: Indicators to <strong>assess baseline</strong> (Iodine Deficiency Disorders) <strong>IDD status</strong> and to <strong>monitor and evaluate</strong> the <strong>impact of salt iodization</strong> on the target population.&nbsp;</span><ul><li><span style=\"font-size:12pt;\"><strong>Urinary Iodine Levels</strong>: The \u2018principal impact indicator\u2019 recommended once a salt iodization programme has been initiated&nbsp;</span></li><li><span style=\"font-size:12pt;\"><strong>Goitre assessment</strong>: (by palpation or by ultrasound) should remain a component of surveys to establish the baseline severity of IDD</span></li><li><span style=\"font-size:12pt;\">&nbsp;<strong>Neonatal thyroid stimulating hormone</strong> (TSH) levels</span></li></ul></li><li><span style=\"font-size:12pt;\"><strong>Sustainability Indicators</strong>: Indicators to assess whether iodine deficiency has been successfully eliminated and maintained.&nbsp;</span><ul><li><span style=\"font-size:12pt;\">Median urinary iodine levels in the target population</span></li><li><span style=\"font-size:12pt;\">Availability of adequately iodized salt at the household level</span></li><li><span style=\"font-size:12pt;\">Set of programmatic indicators (as evidence of sustainability).</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: https://nhm.gov.in/index1.php?lang=1&amp;level=3&amp;sublinkid=1054&amp;lid=230</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p>",
    "correct_choice_id": 8023,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 2035,
    "choices": [
      {
        "id": 8133,
        "text": "<p><span style=\"font-size:12pt;\">50000 IU</span></p>"
      },
      {
        "id": 8134,
        "text": "<p><span style=\"font-size:12pt;\">100000 IU</span></p>"
      },
      {
        "id": 8135,
        "text": "<p><span style=\"font-size:12pt;\">200000 IU</span></p>"
      },
      {
        "id": 8136,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">500000 IU</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 9-month-old child presents to a healthcare clinic in India for a routine check-up. As part of the national health initiatives, the child is due to receive vitamin A supplementation. The healthcare worker prepares to administer the dose as per the national Vitamin A prophylaxis program guidelines. What is the recommended dose of vitamin A solution that should be given to this child?</span></p>",
    "unique_key": "Q3888965",
    "question_audio": null,
    "question_video": null,
    "map_id": 34292,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;B. 100000 IU</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>strategy in Vitamin A prophylaxis program</strong> is to <strong>administer a single massive dose</strong> of <strong>200,000 IU of vitamin A in oil </strong>(retinol palmitate) <strong>orally</strong> every <strong>6 months to preschool children</strong> (1 year to 5 years), and <strong>half that dose</strong> (100,000 IU) to <strong>children between 6 months and one year of age.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Vitamin-A is given at 9th, 18th, 24th, 30th, 36th, 42th, 48th, 54th, 60th months (A total of 1 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac = 17 Lac IU is given to a completely immunized child by 5 years of age)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Vitamin-A</strong> is <strong>administered</strong> by a <strong>2 mL spoon</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Strength of Vitamin-A solution</strong>: 1 lac IU per mL</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The recommended <strong>dose of vitamin A solution for a 9-month-old child</strong> under the <strong>National Vitamin A Prophylaxis Program</strong> is <strong>100,000 International Units</strong> (IU).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 706)</strong></span></p>",
    "correct_choice_id": 8134,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2038,
    "choices": [
      {
        "id": 8145,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ferric ortho phosphate</span></span></p>"
      },
      {
        "id": 8146,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ferrous phosphate</span></span></p>"
      },
      {
        "id": 8147,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ferric chloride</span></span></p>"
      },
      {
        "id": 8148,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ferrous sulphate</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A third-year medical student is rotating through a public health clinic in India and learns about the various strategies to combat nutritional deficiencies. One of the programs discussed is the National Nutritional Anaemia Prophylaxis Programme, which includes the fortification of salt with iron. Which form of iron is utilized for this fortification strategy in the program?</span></span></p>",
    "unique_key": "Q8944532",
    "question_audio": null,
    "question_video": null,
    "map_id": 34293,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;A. Ferric ortho phosphate</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>National Institute of Nutrition</strong>, <strong>Hyderabad</strong> showed that simple <strong>addition</strong> of <strong>ferric ortho-phosphate</strong> or ferrous sulphate with <strong>sodium bisulphate</strong> was enough to <strong>fortify salt with iron</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;<strong>Food fortification: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Is a <strong>public health</strong>, measure where <strong>nutrients are added to food</strong> (in relatively small quantities), to <strong>maintain/improve the quality of diet</strong> of a <strong>group</strong>, community or a population.&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Food Fortification is an example of &lsquo;<strong>Primary Level of Prevention&rsquo;</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Criteria for food fortification:</strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Vehicle to be fortified must be consumed regularly in diet by populations</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Amount of nutrient added must not cause deficiency or toxicity in consumers</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">On addition of nutrient, there should be no change in taste, odour, consistency or appearance</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cost of fortification must be affordable by consumers</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Examples of Food Fortification</strong>:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Iodisation of salt</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Vitamin A and Vitamin D in Vanaspati -&nbsp;Vanaspati is fortified with <strong>&lsquo;2500 IU Vitamin A and 175 IU Vitamin D&rsquo; per 100 &nbsp;grams</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fluoridation of water</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 733)</strong></span></span></p>",
    "correct_choice_id": 8145,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 2323,
    "choices": [
      {
        "id": 9280,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pursue high quality DOTS expansion and enhancement</span></span></p>"
      },
      {
        "id": 9281,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Engage all care providers</span></span></p>"
      },
      {
        "id": 9282,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Empower people with TB and communities</span></span></p>"
      },
      {
        "id": 9283,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Case detection through predominantly passive case finding</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dr. Lokesh, a public health officer, is reviewing the historical efforts in global tuberculosis (TB) control to prepare for a lecture on infectious diseases. She notes that the World Health Organization (WHO) has transitioned from the STOP TB strategy to the more recent END TB strategy.&nbsp;Which of the following was NOT part of the WHO&#39;s previous STOP TB strategy?</span></span></p>",
    "unique_key": "Q7527112",
    "question_audio": null,
    "question_video": null,
    "map_id": 34291,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. Case detection through predominantly passive case finding</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>STOP TB strategy</strong>, <strong>implemented by WHO</strong>, did not <strong>emphasize predominantly passive case finding</strong> as a <strong>major component</strong>. Instead, it <strong>focused on active case</strong> finding as <strong>part of its comprehensive approach</strong> to <strong>TB control</strong>. <strong>Passive case finding</strong> relies on <strong>symptomatic individuals</strong> seeking <strong>healthcare</strong> on their own, which can lead to delays in diagnosis and treatment, thereby increasing the risk of TB transmission. The STOP TB strategy aimed at more proactive measures in identifying cases.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation: </u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Correct:</strong> The <strong>STOP TB strategy</strong> did focus on the <strong>expansion and enhancement of high-quality DOT</strong>S (Directly Observed Treatment, Short-course). DOTS is the foundation of TB control programs under this strategy, emphasizing direct observation of treatment to ensure compliance and effectiveness.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Correct:</strong> <strong>Engaging all care providers</strong> was a <strong>key component of the STOP TB strategy</strong>. This included both public and private healthcare providers, aiming to ensure a coordinated and effective approach to TB treatment and prevention.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Correct:</strong> <strong>Empowering people with TB</strong> and <strong>communities</strong> was also a <strong>vital aspect of the STOP TB strategy.</strong> This involved education, awareness, and community participation to improve TB control efforts and reduce stigma.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>STOP TB strategy:</strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pursue high-quality DOTS expansion and enhancement.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Address TB/HIV, MDR-TB and other challenges.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Contribute to health system strengthening.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Engage all care providers.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Empower people with TB and communities.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Enable and promote research.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Elimination level for Tuberculosis</strong> (WHO and STOP TB Strategy): &lt;1 case per million populations (to eliminate TB as a public health problem)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 233)</strong></span></span></p>",
    "correct_choice_id": 9283,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2128,
    "choices": [
      {
        "id": 8501,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2000</span></span></p>"
      },
      {
        "id": 8502,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2001</span></span></p>"
      },
      {
        "id": 8503,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2004</span></span></p>"
      },
      {
        "id": 8504,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2007</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a discussion about social security initiatives in India, you are teaching 2nd Year MBBS students about the Annapurna Scheme, which aims to support the food needs of indigent senior citizens. When was this scheme launched?</span></span></p>",
    "unique_key": "Q2785722",
    "question_audio": null,
    "question_video": null,
    "map_id": 34337,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;A. 2000&nbsp;&nbsp; </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The Annapurna Scheme is&nbsp;a <strong>central sector scheme</strong> which aims to fulfill the needs of <strong>Senior Citizens</strong> who, despite being eligible, have not received benefits under the National Old Age Pension Scheme (NOAPS). It was launched by the Ministry of Rural Development in 2000&ndash;2001 Under this scheme,&nbsp;<strong>10 Kgs of food grains is distributed per month free of cost</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Annapurna Vs Antodaya</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antyodaya Anna Yojana and Annapurna scheme, both government oriented programs are linked with&nbsp;<strong>public distribution system.&nbsp;Annapurna scheme is for needy senior citizen age of 65 yrs &amp; above&nbsp;and Antyodaya is for the poorest of the poor&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Annapurna Scheme</strong> was launched in <strong>2000</strong> for&nbsp;<strong>needy senior citizen age of 65 yrs</strong> &amp; above&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 563)</strong></span></span></p>",
    "correct_choice_id": 8501,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2011,
    "choices": [
      {
        "id": 8037,
        "text": "<p><span style=\"font-size:12pt;\">Vitamin A prophylaxis programme</span></p>"
      },
      {
        "id": 8038,
        "text": "<p><span style=\"font-size:12pt;\">Anaemia Mukt Bharat</span></p>"
      },
      {
        "id": 8039,
        "text": "<p><span style=\"font-size:12pt;\">National Iodine deficiency disorder control programme</span></p>"
      },
      {
        "id": 8040,
        "text": "<p><span style=\"font-size:12pt;\">Mid-day meal programme</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A first-year PG resident is preparing a presentation on public health initiatives in India and comes across a logo that symbolizes a national campaign. With which of the following public health initiatives is this logo associated?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture43.jpg\" width=\"300\" height=\"339\"></p>",
    "unique_key": "Q9535096",
    "question_audio": null,
    "question_video": null,
    "map_id": 34307,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;B. Anaemia Mukt Bharat</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>Anaemia Mukt Bharat</strong>- <strong>intensified Iron-plus Initiative</strong>&nbsp;aims to <strong>strengthen the existing mechanisms</strong> and <strong>foster newer strategies</strong> for <strong>tackling anaemia</strong>. It <strong>focusses on six target beneficiary groups</strong>, <strong>through six interventions</strong> and <strong>six institutional mechanisms</strong> to achieve the <strong>envisaged target</strong> under the <strong>POSHAN Abhiyan</strong>.</span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://play-lh.googleusercontent.com/MVUfnbDvILIBylE0P851UfBI-s7hvzRIpzW4I2nASfOG8L74GFRwOUSKb17WpKEynt4\" alt=\"Anemia Mukt Bharat - Apps on Google Play\" width=\"400\" height=\"400\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.&nbsp;Vitamin A prophylaxis programme - No specific logo. The logo is for NPCBVI -&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><img src=\"https://npcbvi.mohfw.gov.in/Image/logo1.png\" alt=\"NPCBVI\" width=\"400\" height=\"400\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. National Iodine deficiency disorder control programme -</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><img src=\"https://4.bp.blogspot.com/-8lR48LR1Hg8/WUFz0MhBhuI/AAAAAAAABWA/K0HAayBzQ3wHlOaTDlVCdBrgCjLAHaYMACLcBGAs/s640/Namak.jpg\" alt=\"81 \u0939\u091c\u093e\u0930 \u0915\u094d\u0935\u093f\u0902\u091f\u0932 \u0932\u0947 \u091c\u093e\u0926\u093e \u0906\u092f\u094b\u0921\u0940\u0928 \u0928\u092e\u0915 \u0906\u0935\u0902\u091f\u093f\u0924\" width=\"400\" height=\"267\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Mid-day meal Program&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><img src=\"https://w7.pngwing.com/pngs/697/822/png-transparent-midday-meal-scheme-school-government-of-india-primary-education-school-education-text-class-nutrition.png\" alt=\"Midday Meal Scheme png images | PNGWing\" width=\"400\" height=\"434\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Anemia Mukt Bharat</strong> -&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Main Aim -&nbsp;To <strong>reduce prevalence of anemia</strong> by <strong>3% points per year among children</strong>, <strong>adolescents</strong> and <strong>women in the reproductive age group</strong> (15\u201349 years), between the year <strong>2018-2022</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Beneficiaries</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Children (6\u201359 months)</span></li><li><span style=\"font-size:12pt;\">Children (5\u20139 years)</span></li><li><span style=\"font-size:12pt;\">Adolescent boys (10\u201319 years)</span></li><li><span style=\"font-size:12pt;\">Adolescent girls (10\u201319 years)</span></li><li><span style=\"font-size:12pt;\">Women of reproductive age (20\u201324 years)</span></li><li><span style=\"font-size:12pt;\">Pregnant women</span></li><li><span style=\"font-size:12pt;\">Lactating women</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Interventions</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Prophylactic Iron Folic Acid supplementation</span></li><li><span style=\"font-size:12pt;\">Deworming</span></li><li><span style=\"font-size:12pt;\">Intensified year-round BCC Campaign including ensuring delayed cord clamping</span></li><li><span style=\"font-size:12pt;\">Testing of anemia using digital methods and point of care treatment</span></li><li><span style=\"font-size:12pt;\">Mandatory provision of Iron Folic Acid fortified foods in public health programmes</span><br><span style=\"font-size:12pt;\">\u2022 Addressing non-nutritional causes of anemia in endemic pockets, with special focus on malaria, haemoglobinopathies and fluorosis</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Prophylactic Dose and Regime for Iron Folic Acid Supplementation</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-131218.png\" alt=\"\" width=\"1000\" height=\"570\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: </strong></span><a href=\"https://anemiamuktbharat.info/\"><span style=\"font-size:12pt;\"><strong><u>https://anemiamuktbharat.info/</u></strong></span></a></p>",
    "correct_choice_id": 8038,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 2015,
    "choices": [
      {
        "id": 8053,
        "text": "<p><span style=\"font-size:12pt;\">Vitamin A prophylaxis programme</span></p>"
      },
      {
        "id": 8054,
        "text": "<p><span style=\"font-size:12pt;\">ICDS programme</span></p>"
      },
      {
        "id": 8055,
        "text": "<p><span style=\"font-size:12pt;\">National Iodine deficiency disorder control programme</span></p>"
      },
      {
        "id": 8056,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Mid-day meal programme</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The following logo is associated with which of the following nutritional supplementation programme.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture42.jpg\" width=\"500\" height=\"479\"></p>",
    "unique_key": "Q7781420",
    "question_audio": null,
    "question_video": null,
    "map_id": 34310,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;B. ICDS programme</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B:</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Integrated Child Development Services</strong>&nbsp;(ICDS) is a <strong>government program</strong> in <strong>India</strong> which provides <strong>nutritional meals</strong>,&nbsp;<strong>preschool&nbsp;education</strong>,&nbsp;<strong>primary healthcare</strong>, <strong>immunization</strong>, <strong>health check-up</strong> and <strong>referral services</strong> to <strong>children under 6 years</strong> of age and <strong>their mothers.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://e7.pngegg.com/pngimages/832/488/png-clipart-integrated-child-development-services-all-india-federation-of-anganwadi-workers-and-helpers-child-child-text.png\" alt=\"Integrated Child Development Services All India Federation of Anganwadi  Workers and Helpers, child, child, text png | PNGEgg\" width=\"400\" height=\"294\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Vitamin A prophylaxis programme:&nbsp;</strong>No specific logo. The logo is for<strong> NPCBVI -&nbsp;</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image-20240110185917-1.png\" width=\"400\" height=\"400\"></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. National Iodine deficiency disorder control programme:&nbsp;</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_xWWj4Wj.png\" width=\"400\" height=\"267\"></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Mid-day meal -&nbsp;</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_PlSWQBq.png\" width=\"200\" height=\"217\"></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p><span style=\"font-size:12pt;\"><strong>Integrated Child Development Services</strong> (ICDS)</span></p><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\"><strong>ICDS</strong> (Anganwadi worker) <strong>covered under Ministry Women</strong> and <strong>Child Development</strong></span></li><li><span style=\"font-size:12pt;\"><strong>ICDS</strong> is a <strong>centrally sponsored scheme</strong></span></li><li><span style=\"font-size:12pt;\">Integrated Child Development Services (ICDS) <strong>launched in year 1975</strong></span></li><li><span style=\"font-size:12pt;\"><strong>ICDS Beneficiaries</strong> (Irrespective of income of family)</span><ul><li><span style=\"font-size:12pt;\">Children 0 \u2013 6 years age</span></li><li><span style=\"font-size:12pt;\">Pregnant and lactating mothers</span></li><li><span style=\"font-size:12pt;\">Women in reproductive age group.</span></li><li><span style=\"font-size:12pt;\">Adolescent girls 11 \u2013 18 years</span></li></ul></li><li><span style=\"font-size:12pt;\">ICDS provides an integrated package of services -&nbsp;</span><ul><li><span style=\"font-size:12pt;\">Supplementary nutrition</span></li><li><span style=\"font-size:12pt;\">Immunization</span></li><li><span style=\"font-size:12pt;\">Health check-up</span></li><li><span style=\"font-size:12pt;\">Medical referral services</span></li><li><span style=\"font-size:12pt;\">Nutrition and health education for women</span></li><li><span style=\"font-size:12pt;\">Non-formal education for children aged 3 \u2013 6 years, and pregnant and nursing mothers in rural, urban and tribal areas</span></li></ul></li><li><span style=\"font-size:12pt;\">\u2018<strong>Heart of ICDS system\u2019</strong> - Anganwadi</span></li><li><span style=\"font-size:12pt;\"><strong>Population</strong> covered by <strong>Anganwadi in tribal area</strong> - <strong>300-800</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Population</strong> covered by <strong>Anganwadi in plains area</strong> - <strong>400-800</strong></span></li><li><span style=\"font-size:12pt;\"><strong>1 Mini-Anganwadi centre</strong> per <strong>150\u2013400 population</strong> (rural/urban); 150-300 (tribal)</span></li><li><span style=\"font-size:12pt;\"><strong>1 Anganwadi on Demand</strong> (AOD) for <strong>settlement \u2265 40 children</strong> under <strong>6 years age</strong></span></li><li><span style=\"font-size:12pt;\">Supplemental nutrition given through ICDS: 300 feeding days in a year [NEW 2014 GUIDELINES]</span></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\">&nbsp;</span></p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-131644.png\" alt=\"\" width=\"1000\" height=\"433\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: ICDS document, Ministry of Women &amp; Child Development, Government of India</strong></span></p>",
    "correct_choice_id": 8054,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 2018,
    "choices": [
      {
        "id": 8065,
        "text": "<p><span style=\"font-size:12pt;\">Poshan Abhiyaan</span></p>"
      },
      {
        "id": 8066,
        "text": "<p><span style=\"font-size:12pt;\">ICDS programme</span></p>"
      },
      {
        "id": 8067,
        "text": "<p><span style=\"font-size:12pt;\">National Iodine deficiency disorder control programme</span></p>"
      },
      {
        "id": 8068,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Mid-day meal programme</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A public health intern is given a task to develop educational materials for a nationwide campaign in India. As part of this task, the intern is reviewing various logos associated with different health programs. One particular logo that the intern has to work with is designed to represent the government's flagship program to improve nutritional outcomes for children, pregnant women, and lactating mothers. Which of the following national health programs does this logo represent?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture41.jpg\" width=\"250\" height=\"429\"></p>",
    "unique_key": "Q1011235",
    "question_audio": null,
    "question_video": null,
    "map_id": 34296,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;A. Poshan Abhiyaan</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A:</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Poshan Abhiyaan</strong> was <strong>launched by Hon\u2019ble Prime Minister</strong> on <strong>8th March 2018</strong> in <strong>Jhunjhunu district of Rajasthan</strong>. The <strong>focus of Abhiyaan</strong> is to <strong>lay emphasis</strong> on <strong>nutritional status</strong> of <strong>adolescent girls</strong>, <strong>pregnant women</strong>, <strong>lactating mothers</strong>, and <strong>children from 0-6 years age</strong>. The programme, <strong>through use of technology</strong>, <strong>convergence</strong> and <strong>community involvement</strong> with a <strong>targeted approach strives</strong> to <strong>reduce the level of stunning</strong>, <strong>under-nutrition</strong>, <strong>Anaemia</strong>, and <strong>low birth weight</strong> in children, as also focus on adolescent girls, pregnant women and lactating mothers, thus holistically addressing malnutrition.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://static.virtubox.io/project/file/20220115-045727-dfhl-poshan-abhiyaan-logo.png\" alt=\"Poshan Abhiyaan Logo\" width=\"300\" height=\"300\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\">Synonym -&nbsp;<strong>National Nutrition Mission</strong> (NNM)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. ICDS Programme</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://e7.pngegg.com/pngimages/832/488/png-clipart-integrated-child-development-services-all-india-federation-of-anganwadi-workers-and-helpers-child-child-text.png\" alt=\"Integrated Child Development Services All India Federation of Anganwadi  Workers and Helpers, child, child, text png | PNGEgg\" width=\"400\" height=\"294\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.&nbsp;National Iodine deficiency disorder control programme</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_jx9eRYa.png\" width=\"400\" height=\"406\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D.&nbsp;Mid-day meal programme</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_K6A2ZSV.png\" width=\"400\" height=\"391\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Poshan Abhiyaan</strong>/ NNM -&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Major impact</strong>: To <strong>reduce</strong> the level of <strong>stunting</strong>, <strong>under-nutrition</strong>, <strong>anemia</strong> and low birth weight babies.&nbsp;</span></li><li><span style=\"font-size:12pt;\"><strong>Components</strong>: Mapping of various Schemes contributing towards addressing malnutrition, Introducing&nbsp;a very robust convergence mechanism, ICT based Real Time Monitoring system, Incentivizing&nbsp;States/UTs for meeting the targets, Incentivizing Anganwadi Workers (AWWs) for&nbsp;using IT based tools, Eliminating registers used by AWWs, Introducing measurement of height&nbsp;of children at the Anganwadi Centres (AWCs), Social Audits, Setting-up Nutrition Resource&nbsp;Centres, involving masses through Jan Andolan</span></li><li><span style=\"font-size:12pt;\"><strong>Vision</strong>: To ensure attainment of malnutrition-free India by 2022</span></li><li><span style=\"font-size:12pt;\"><strong>Targets</strong>:</span><ul><li><span style=\"font-size:12pt;\">To reduce stunting, under- nutrition, anemia (among young children, women and adolescent girls) and reduce low birth weight by 2%, 2%, 3% and 2% per annum respectively</span></li><li><span style=\"font-size:12pt;\">Although the target to reduce Stunting is at least 2% p.a., Mission would strive to achieve reduction in Stunting from 38.4% (NFHS-4) to 25% by 2022<strong> </strong>(Mission 25 by 2022)</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: </strong></span><a href=\"https://wcd.nic.in/schemes/poshan-abhiyaan\"><span style=\"font-size:12pt;\"><strong><u>https://wcd.nic.in/schemes/poshan-abhiyaan</u></strong></span></a></p><p>&nbsp;</p>",
    "correct_choice_id": 8065,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 2022,
    "choices": [
      {
        "id": 8081,
        "text": "<p><span style=\"font-size:12pt;\">ICDS programme</span></p>"
      },
      {
        "id": 8082,
        "text": "<p><span style=\"font-size:12pt;\">Anaemia Mukt Bharat</span></p>"
      },
      {
        "id": 8083,
        "text": "<p><span style=\"font-size:12pt;\">Balwadi nutrition programme</span></p>"
      },
      {
        "id": 8084,
        "text": "<p><span style=\"font-size:12pt;\">Mid-day meal scheme</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A public health official is reviewing various nutritional programs to address child malnutrition in India. During a presentation, a specific logo is displayed that is representative of a national program. With which of the following national health programs is this logo associated?</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture40.jpg\" width=\"300\" height=\"297\"></p>",
    "unique_key": "Q4579874",
    "question_audio": null,
    "question_video": null,
    "map_id": 34299,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. Mid-day meal scheme</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\">The&nbsp;<strong>Mid-Day Meal Scheme</strong>&nbsp;is a&nbsp;<strong>school meal&nbsp;programme</strong> in <strong>India</strong> designed to <strong>better the&nbsp;nutritional&nbsp;standing</strong> of <strong>school-age children nationwide</strong>.&nbsp;The <strong>programme</strong> supplies <strong>free lunches</strong> on <strong>working days for children</strong> in <strong>government primary</strong> and <strong>upper primary schools</strong>, government aided&nbsp;Anganwadis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/07/image-20231107205846-1.png\" width=\"400\" height=\"433\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. ICDS&nbsp;programme -&nbsp;</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://e7.pngegg.com/pngimages/832/488/png-clipart-integrated-child-development-services-all-india-federation-of-anganwadi-workers-and-helpers-child-child-text.png\" alt=\"Integrated Child Development Services All India Federation of Anganwadi  Workers and Helpers, child, child, text png | PNGEgg\" width=\"400\" height=\"294\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. Anemia Mukt Bharat -&nbsp;</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_5kYEG43.png\" width=\"400\" height=\"400\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Balwadi nutrition programme - No specific logo</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Mid-day meal scheme</strong> (MDMS) (National Programme of Nutritional Support to Primary Education):</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Launched in <strong>1995</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Main objective</strong>: Universalisation of primary education by increasing enrolment, retention and&nbsp;attendance and simultaneously impacting on nutrition of students in primary classes.&nbsp;</span></li><li><span style=\"font-size:12pt;\">The <strong>mid-day meal</strong> should <strong>supply 1/3 of the total energy requirement</strong> and <strong>1/2 of the total&nbsp;protein requirement</strong></span></li><li><span style=\"font-size:12pt;\">A model menu for mid-day school meal -&nbsp;</span></li></ul><p>&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-132403.png\" alt=\"\" width=\"1000\" height=\"312\"></p><ul><li><span style=\"font-size:12pt;\"><strong>Principles for formulating mid-day meals:&nbsp;</strong></span><ul><li><span style=\"font-size:12pt;\">Meal should be a supplement only not a substitute for home diet</span></li><li><span style=\"font-size:12pt;\">Meal should provide 1/3 calories and 1/2 proteins</span></li><li><span style=\"font-size:12pt;\">Meal cost should be low</span></li><li><span style=\"font-size:12pt;\">Complicated cooking process must not be involved</span></li><li><span style=\"font-size:12pt;\">Use locally available foods</span></li><li><span style=\"font-size:12pt;\">Keep changing menu frequently</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: </strong></span><a href=\"https://en.wikipedia.org/wiki/Midday_Meal_Scheme\"><span style=\"font-size:12pt;\"><strong><u>https://en.wikipedia.org/wiki/Midday_Meal_Scheme</u></strong></span></a></p>",
    "correct_choice_id": 8084,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 2041,
    "choices": [
      {
        "id": 8157,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">100 mg of elemental iron and 0.5 mg of folic acid</span></span></p>"
      },
      {
        "id": 8158,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">20 mg of elemental iron and 0.1 mg of folic acid</span></span></p>"
      },
      {
        "id": 8159,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">30 mg of elemental iron and 0.25 mg of folic acid</span></span></p>"
      },
      {
        "id": 8160,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">60 mg of elemental iron and 0.4 mg of folic acid</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As a medical officer in a rural health center in India, you are counseling a parent about the prophylactic administration of iron and folic acid to their 8-year-old child, in line with the National Nutritional Anaemia Prophylaxis Programme. What is the recommended daily dose of iron and folic acid to be administered to this child for a period of 100 days?</span></span></p>",
    "unique_key": "Q8237282",
    "question_audio": null,
    "question_video": null,
    "map_id": 34306,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 30 mg of elemental iron and 0.25 mg of folic acid</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>IFA Tablet&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">An <strong>adult tablet of IFA contains</strong>: <strong>100 mg elemental Iron</strong> (300 mg ferrous sulfate) and <strong>500 mcg Folic acid</strong> (to be given for 100 days minimum in pregnancy) and <strong>100 days post-delivery</strong>&nbsp;&ndash; Schedule: 1 Tablet per day in 4-5-6 month POG (Total 100 tablets)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adolescents</strong> are given the <strong>same dosage</strong> and <strong>duration as adults</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Children 6-10 years of age</strong> are to be provided <strong>30 mg elemental iron</strong> and <strong>250 mcg folic acid</strong> per day for <strong>100 days</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A <strong>pediatric tablet of IFA contains</strong>: <strong>20 mg elemental Iron</strong> and <strong>100 mcg Folic acid</strong> (to be given for 100 days minimum every year till 5 years age of child)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&lsquo;National Nutritional Anemia Prophylaxis Programme&rsquo;</strong> was launched in <strong>1970 to prevent nutritional&nbsp;anaemia</strong> in <strong>mothers and children</strong>. This programme is being taken up by MCH Division of Ministry of Health and Family Welfare; now it is part of RCH programme</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Iron and Folic Acid content per IFA tablet</strong>:&nbsp;<br />\r\n\t<strong>Adult tablet</strong>: 100 mg elemental iron and 500 mcg folic acid</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Pediatric tablet</strong>: 20 mg elemental iron and 100 mcg folic acid</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>For preterm infants, IFA tablet: 10 &ndash; 15 mg elemental iron and 100 mcg folic acid</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 733)</strong></span></span></p>",
    "correct_choice_id": 8159,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2044,
    "choices": [
      {
        "id": 8169,
        "text": "<p><span style=\"font-size:12pt;\">Behaviour change communication for one month in a year</span></p>"
      },
      {
        "id": 8170,
        "text": "<p><span style=\"font-size:12pt;\">Testing of anaemia using digital methods</span></p>"
      },
      {
        "id": 8171,
        "text": "<p><span style=\"font-size:12pt;\">Addressing non nutritional causes of anaemia</span></p>"
      },
      {
        "id": 8172,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Provision of iron fortified foods in health programmes</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A public health student is preparing a presentation on the \"Anaemia Mukt Bharat\" initiative, which aims to reduce the prevalence of anaemia across various age groups in India. She is outlining the key interventions promoted by this strategy. Which of the following is NOT an intervention included in the Anaemia Mukt Bharat strategy?</span></p>",
    "unique_key": "Q6244700",
    "question_audio": null,
    "question_video": null,
    "map_id": 34308,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;A. Behaviour change communication for one month in a year</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">This is the <strong>intervention under AMB program</strong>.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Interventions in Anaemia Mukt Bharat are</strong> -&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">1. <strong>Prophylactic Iron</strong> and <strong>Folic Acid supplementation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">2. <strong>Deworming</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">3. <strong>Intensified year-round Behaviour Change Communication Campaign</strong> (Solid Body, Smart Mind) including ensuring delayed cord clamping in newborns</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">4. Testing of anaemia using digital methods <strong>(Option B</strong>) and point of care treatment</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">5. Mandatory provision of Iron and Folic Acid fortified foods <strong>(Option D)</strong> in government-funded health programmes</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">6. Addressing non-nutritional causes of anaemia <strong>(Option C)</strong> in endemic pockets, with special focus on malaria, haemoglobinopathies and fluorosis</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Anaemia Mukt Bharat Program&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Main Aim</strong> -&nbsp;To <strong>reduce prevalence of anemia</strong> by <strong>3% points per year</strong> among <strong>children</strong>, adolescents and women in the reproductive age group (15\u201349 years), between the year 2018-2022</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Beneficiaries</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12pt;\">Children (6\u201359 months)</span></li><li><span style=\"font-size:12pt;\">Children (5\u20139 years)</span></li><li><span style=\"font-size:12pt;\">Adolescent boys and girls (10\u201319 years)&nbsp;</span></li><li><span style=\"font-size:12pt;\">Women of reproductive age (20\u201324 years)</span></li><li><span style=\"font-size:12pt;\">Pregnant women&nbsp;</span></li><li><span style=\"font-size:12pt;\">Lactating women&nbsp;</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Institutional Mechanism -&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image_jQNMeyX.png\" width=\"539\" height=\"207\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Anemia Mukt Bharat 6X6X6 Strategy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image.png\" width=\"410\" height=\"327\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: </strong></span><a href=\"https://anemiamuktbharat.info/home/interventions/\"><span style=\"font-size:12pt;\"><strong><u>https://anemiamuktbharat.info/home/interventions/</u></strong></span></a></p>",
    "correct_choice_id": 8169,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 2050,
    "choices": [
      {
        "id": 8193,
        "text": "<p><span style=\"font-size:12pt;\">Children 6-59 months of age</span></p>"
      },
      {
        "id": 8194,
        "text": "<p style=\"text-align:justify;\"><span style=\"color:black;font-size:12pt;\">Children 5-9 years of age</span></p>"
      },
      {
        "id": 8195,
        "text": "<p><span style=\"font-size:12pt;\">Adolescent girls and boy 10-19 years of age</span></p>"
      },
      {
        "id": 8196,
        "text": "<p><span style=\"font-size:12pt;\">Women in age group of 50-60 years</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">You are a physician working on public health planning in a semi-urban district of Himachal Pradesh, India. Your current project involves implementing the \"Anaemia Mukt Bharat\" strategy, a key initiative of the government to combat anaemia. According to the program guidelines, which group of individuals is NOT a primary target for anaemia interventions under the \"Anaemia Mukt Bharat\" initiative?</span></p>",
    "unique_key": "Q8785293",
    "question_audio": null,
    "question_video": null,
    "map_id": 34297,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. Women in age group of 50-60 years</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Beneficiaries in Anaemia Mukt Bharat</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture39.jpg\" width=\"700\" height=\"167\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Anaemia Mukt Bharat Program&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Main Aim</strong> -&nbsp;To <strong>reduce prevalence</strong> of <strong>anemia by 3% points per year among children</strong>, <strong>adolescents</strong> and <strong>women in the reproductive age group</strong> (15\u201349 years), between the year <strong>2018-2022</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Anemia Mukt Bharat 6X6X6 Strategy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108094621-2.png\" width=\"410\" height=\"327\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Institutional Mechanism -&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108094621-1.png\" width=\"539\" height=\"207\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Interventions -&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108094621-3.jpeg\" width=\"424\" height=\"306\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Anemia Mukt Bharat Beneficiaries</strong> are&nbsp;<strong>Children</strong> (6\u201359 months),&nbsp;<strong>Children</strong> (5\u20139 years),&nbsp;<strong>Adolescent boys &amp; girls</strong> (10\u201319 years),&nbsp;<strong>Women of reproductive age</strong> (20\u201324 years),&nbsp;<strong>Pregnant</strong> and <strong>lactating women</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Prophylactic Dose and Regime for Iron Folic Acid Supplementation</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-145806.png\" alt=\"\" width=\"1000\" height=\"558\"></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Ref</u>: </strong></span><a href=\"https://anemiamuktbharat.info/home/6x6x6-strategy/\"><span style=\"font-size:12pt;\"><strong><u>https://anemiamuktbharat.info/home/6x6x6-strategy/</u></strong></span></a></p>",
    "correct_choice_id": 8196,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2059,
    "choices": [
      {
        "id": 8229,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Malaria</span></span></p>"
      },
      {
        "id": 8230,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hemoglobinopathies</span></span></p>"
      },
      {
        "id": 8231,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fluorosis</span></span></p>"
      },
      {
        "id": 8232,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tuberculosis</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A medical officer is evaluating the strategic areas of focus in the &quot;Anaemia Mukt Bharat&quot; initiative to organize a health camp in a rural district. Which of the following conditions is NOT given special focus under the &quot;Anaemia Mukt Bharat&quot; program?</span></span></p>",
    "unique_key": "Q2181668",
    "question_audio": null,
    "question_video": null,
    "map_id": 34302,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. Tuberculosis</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Special focus on non-nutritional</strong> causes under the <strong>&quot;Anaemia Mukt Bharat&quot; program</strong> are <strong>Malaria</strong>, <strong>Hemoglobinopathies</strong> and <strong>fluorosis</strong>; NOT TB</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>6th Intervention Out Of 6</strong> -&nbsp;Intensifying awareness, screening and treatment of non-nutritional causes of anemia in endemic pockets, with special focus on malaria, haemoglobinopathies and fluorosis</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Malaria:&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Intensification of malaria prevention</strong> and <strong>control activities in integration</strong> with <strong>nutritional anemia</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fixed days for screening of anemia at PMSMA sites and annually by RBSK teams in schools for screening for malaria as per NVBDCP, MoHFW guidelines. </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Indoor Residual Spray (IRS) before and after the monsoon season in school premises and residential areas and provide Long Lasting Insecticide Nets (LLINs) in all high endemic areas esp. to all target groups pregnant mothers and under-five children </span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Haemoglobinopathies:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Comprehensive prevention</strong>, <strong>screening</strong> and <strong>management of haemoglobinopathies</strong> - <strong>Pre-marital</strong> and <strong>pre-conception screening</strong> and <strong>counselling services</strong> </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Women identified with severe anemia should be referred to higher centres for further investigations and if found positive, the husband is to be screened for carrier status. If the couple is found positive, they are to be referred to a higher centre for prenatal diagnosis before twenty weeks of pregnancy.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>treatment of anemia</strong> using <strong>parental iron administration</strong> is contraindicated in <strong>sickle cell disease</strong> patients.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Fluorosis:&nbsp;The 3 key interventions are:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Identification of Fluoride-Affected Habitations</strong>:</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Activities for Anemia Control Due to Fluorosis</strong>: use of safe drinking water, focus on diet corrections (Calcium, Magnesium, Vitamin C) by dietary diversity, periodic check-up of haemoglobin in affected habitations and appropriate treatment, IFA supplementation. </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Capacity Building/Training of all public health staff</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Anemia Mukt Bharat 6X6X6 Strategy</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108095947-1.png\" style=\"height:319px; width:400px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Beneficiaries</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children (6&ndash;59 months)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children (5&ndash;9 years)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Adolescent boys and girls (10&ndash;19 years)&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Women of reproductive age (20&ndash;24 years)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pregnant women&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Lactating women&nbsp;</span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Institutional Mechanism -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108095947-2.png\" style=\"height:154px; width:400px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Interventions in Anaemia Mukt Bharat</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108095947-3.jpeg\" style=\"height:409px; width:566px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: </strong><a href=\"https://anemiamuktbharat.info/home/6x6x6-strategy/\" style=\"color:#0563c1; text-decoration:underline\"><strong>https://anemiamuktbharat.info/home/6x6x6-strategy/</strong></a></span></span></p>",
    "correct_choice_id": 8232,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2067,
    "choices": [
      {
        "id": 8261,
        "text": "<p><span style=\"font-size:12pt;\">10 children under 6 years of age</span></p>"
      },
      {
        "id": 8262,
        "text": "<p><span style=\"font-size:12pt;\">20 children under 6 years of age</span></p>"
      },
      {
        "id": 8263,
        "text": "<p><span style=\"font-size:12pt;\">30 children under 6 years of age</span></p>"
      },
      {
        "id": 8264,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">40 children under 6 years of age</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">As a public health administrator, you are evaluating a proposal for establishing a new 'Anganwadi on demand' in a remote settlement. According to the guidelines, what is the minimum criterion regarding population or households for setting up an 'Anganwadi on demand'?</span></p>",
    "unique_key": "Q6257028",
    "question_audio": null,
    "question_video": null,
    "map_id": 34304,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. 40 children under 6 years of age</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Anganwadi on demand</strong> - where a <strong>settlement</strong> has <strong>at least 40 children under 6 years</strong> but <strong>no Anganwadis centre</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Heart of ICDS system</strong>: Anganwadi</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Focal point</strong> for ICDS services delivery is Anganwadi Worker; <strong>Each Anganwadi has 1 Anganwadi worker</strong> and <strong>1 helper</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">1 Anganwadi centre per <strong>400\u2013800 population</strong> in <strong>rural and urban areas</strong></span></li><li><span style=\"font-size:12pt;\">1 Anganwadi centre per <strong>300\u2013800 population </strong>in <strong>tribal areas</strong></span></li><li><span style=\"font-size:12pt;\">1 Mini-Anganwadi centre per <strong>150\u2013400 population</strong> (rural/urban); <strong>150-300</strong> (tribal)</span></li><li><span style=\"font-size:12pt;\"><strong>1 Anganwadi on Demand</strong> (AOD) for <strong>settlement \u2265 40 children</strong> under <strong>6 years age</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>1 Anganwadi on Demand</strong> (AOD) for <strong>settlement \u2265 40 children</strong> under <strong>6 years age</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u></strong>: <strong>Park 26<sup>th</sup> edition (page 680)</strong></span></p>",
    "correct_choice_id": 8264,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2148,
    "choices": [
      {
        "id": 8581,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2011</span></span></p>"
      },
      {
        "id": 8582,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2012</span></span></p>"
      },
      {
        "id": 8583,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2010</span></span></p>"
      },
      {
        "id": 8584,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2013</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A 6-year-old girl is brought to a primary health care center in a rural area of India for a routine health check-up. Her parents are concerned about her nutritional status and have heard about government programs that offer supplementation for children. You recall that the National Iron Plus Initiative addresses the prevention and treatment of iron-deficiency anemia across different age groups.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">What is the launch year of the government initiative that you would discuss with the parents to ensure the child receives appropriate iron supplementation?</span></span></p>",
    "unique_key": "Q3014471",
    "question_audio": null,
    "question_video": null,
    "map_id": 34298,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;D. 2013</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In&nbsp;<strong>2013</strong>, <strong>MoHFW expanded the NNACP </strong>and <strong>renamed</strong> it as a <strong>National Iron Plus Initiative</strong> (NIPI) <strong>programme</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>National Iron PLUS Initiative</strong> is an attempt to look at <strong>Iron Deficiency Anaemia</strong> in which <strong>beneficiaries</strong> will receive <strong>iron and folic acid supplementation</strong> irrespective of their <strong>Iron/hemoglobin status</strong>.&nbsp;Thus its <strong>Primary level of prevention</strong> (Specific protection)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>National Iron Plus Initiative</strong> was launched in <strong>2013</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>IFA SUPPLEMENTATION</strong> - Prophylactic doses and regimen</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-153142.png\" style=\"height:559px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 557)</strong></span></span></p>",
    "correct_choice_id": 8584,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2153,
    "choices": [
      {
        "id": 8601,
        "text": "<p><span style=\"font-size:12pt;\">2004</span></p>"
      },
      {
        "id": 8602,
        "text": "<p><span style=\"font-size:12pt;\">2006</span></p>"
      },
      {
        "id": 8603,
        "text": "<p><span style=\"font-size:12pt;\">2008</span></p>"
      },
      {
        "id": 8604,
        "text": "<p><span style=\"font-size:12pt;\">2010</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A 35-year-old food inspector is participating in a workshop about food safety regulations in India. He is asked about the historical context of food regulatory bodies in India. He recalls that the current regulatory body, the Food Safety and Standards Authority of India (FSSAI), was operationalized under the Food Safety and Standards Act of 2006. In which year was the FSSAI officially established?</span></p>",
    "unique_key": "Q8929186",
    "question_audio": null,
    "question_video": null,
    "map_id": 34300,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. 2008</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>Food Safety</strong> and <strong>Standards Authority of India</strong> (FSSAI) was established in the <strong>year 2008</strong><i>. </i><strong>FSSAI Act 2006</strong> is being <strong>implemented by all states/UT governments</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>FOOD SAFETY AND STANDARDS AUTHORITY OF INDIA</strong> (FSSAI)</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Background</strong>: Established under <strong>Food Safety and Standards Act, 2006</strong></span></li><li><span style=\"font-size:12pt;\">Head office: New Delhi</span></li><li><span style=\"font-size:12pt;\"><strong>Objectives:</strong></span><ul><li><span style=\"font-size:12pt;\">To introduce a single statute relating to food</span></li><li><span style=\"font-size:12pt;\">To provide for the scientific development of the food processing industry</span></li></ul></li></ul><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Function</strong>:&nbsp;</span><ul><li><span style=\"font-size:12pt;\">Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption</span></li><li><span style=\"font-size:12pt;\">Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed</span></li><li><span style=\"font-size:12pt;\">Single reference point for all matters relating to food safety and standards</span></li></ul></li><li><span style=\"font-size:12pt;\"><strong>Administrative Ministry for the implementation</strong> -&nbsp;Ministry of Health &amp; Family Welfare, GoI</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Food Safety</strong> and <strong>Standards Authority of India</strong> (FSSAI) was established in the <strong>year 2008</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Administrative Ministry for the implementation</strong> -&nbsp;Ministry of Health &amp; Family Welfare, GoI</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 749)</strong></span></p>",
    "correct_choice_id": 8603,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 2186,
    "choices": [
      {
        "id": 8733,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">0.01 mg per 100 grams of food material</span></span></p>"
      },
      {
        "id": 8734,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">0.02 mg per 100 grams of food material</span></span></p>"
      },
      {
        "id": 8735,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">0.05 mg per 100 grams of food material</span></span></p>"
      },
      {
        "id": 8736,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">0.10 mg per 100 grams of food material</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of food safety,&nbsp;A medical resident is reviewing food safety regulations concerning grain products. He notes that certain regulations specify maximum allowable concentrations of natural contaminants. What is the upper safe limit for ergot alkaloids in food material, as per safety guidelines?</span></span></p>",
    "unique_key": "Q9819123",
    "question_audio": null,
    "question_video": null,
    "map_id": 34301,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;C. 0.05 mg per 100 grams of food material</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>upper safe limit</strong> for the <strong>ergot alkaloids</strong> has been <strong>estimated to be 0.05 mg per 100 grams</strong> of the <strong>food material</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ergotism</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Description: Occurs due to <strong>food toxicant</strong> - ergot fungus &lsquo;Claviceps fusiformis&rsquo; (Toxin - Clavine alkaloids)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Removal of ergot</strong>:&nbsp;&ndash; Float them in 20% salt water</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hand-picking</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Air-floatation</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Upper safe limit for ergot</strong> - <strong>0.05 mg</strong> per <strong>100 grams food material</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Food items</strong> having a <strong>tendency for ergotism</strong>&nbsp;&ndash; Bajra,&nbsp;Rye,&nbsp;Sorghum,&nbsp;Wheat</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 747)</strong></span></span></p>",
    "correct_choice_id": 8735,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2325,
    "choices": [
      {
        "id": 9288,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Address TB/HIV, MDR TB and other challenges</span></span></p>"
      },
      {
        "id": 9289,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Integrated patient centred care and prevention</span></span></p>"
      },
      {
        "id": 9290,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Bold policies and supportive systems</span></span></p>"
      },
      {
        "id": 9291,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Intensified research and innovation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">As part of an initiative to contribute to the END TB strategy, a team of public health professionals is developing a comprehensive plan to combat tuberculosis (TB). They are focusing on the three pillars that underpin the strategy, which were set forth by the World Health Organization (WHO). Which of the following is NOT one of the pillars of the END TB strategy as set by the World Health Organization?</span></span></p>",
    "unique_key": "Q1840123",
    "question_audio": null,
    "question_video": null,
    "map_id": 34305,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Address TB/HIV, MDR TB and other challenges</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">While <strong>addressing TB/HIV co-infection</strong>, <strong>multidrug-resistant TB</strong> (MDR TB), and other challenges is crucial in the <strong>fight against tuberculosis</strong>, it is not listed as one of the distinct pillars of the WHO&#39;s END TB strategy. </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>End TB Strategy 2016-2035</strong> - with Vision of <strong>&quot;A world free of TB and&nbsp;Zero deaths, disease and suffering due to TB</strong>&quot; END TB strategy.&nbsp;The three core pillars of the WHO&rsquo;s END TB strategy, which are essential for planning and executing TB control programs are -&nbsp;Integrated, patient-centred care and prevention,&nbsp;Bold policies and supportive systems and&nbsp;Intensified research and innovation.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Integrated, patient-centered care and prevention:</strong> <strong>Focusing</strong> on <strong>early diagnosis</strong>, treatment, and care for all, including vulnerable populations.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Bold policies and supportive systems:</strong> This involves <strong>strengthening health systems</strong> and improving social determinants of health.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Intensified research and innovation:</strong> Aiming to <strong>advance new tools</strong> for <strong>diagnosis</strong>, <strong>treatment</strong>, and <strong>vaccines</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>End TB Strategy 2016-2035 </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Goal: End the Global TB Epidemic</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-171552.png\" style=\"height:432px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 233)</strong></span></span></p>",
    "correct_choice_id": 9288,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2334,
    "choices": [
      {
        "id": 9324,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Agra</span></span></p>"
      },
      {
        "id": 9325,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Bhopal</span></span></p>"
      },
      {
        "id": 9326,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chennai</span></span></p>"
      },
      {
        "id": 9327,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Delhi</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical student is assigned to prepare a presentation on tuberculosis research institutions in India as part of their infectious diseases rotation. They need to locate the leading research institution where significant work on tuberculosis (TB) is conducted, including clinical trials, drug resistance studies, and epidemiological research. The National Institute for Research in Tuberculosis (NIRT), a premier institute dedicated to TB research in India, is located in which city?</span></span></p>",
    "unique_key": "Q2287958",
    "question_audio": null,
    "question_video": null,
    "map_id": 34309,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Chennai</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>National Institute for Research in Tuberculosis</strong> (NIRT), formerly known as the <strong>Tuberculosis Chemotherapy Centre</strong>, is situated in <strong>Chennai</strong>. It is <strong>one of the institutes</strong> of the <strong>Indian Council of Medical Research </strong>(ICMR) and plays a <strong>pivotal role in TB research in India</strong>. NIRT conducts a wide array of research activities related to tuberculosis, including basic science research, clinical trials, and epidemiological studies.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>National reference Laboratories for TB in India</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">National Institute for Research in Tuberculosis (NIRT), Chennai</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">National Tuberculosis Institute (NTI), Bangalore</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">National Institute of TB and Respiratory Diseases (NITRD), Delhi</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Delhi and National Japanese Leprosy Mission for Asia (JALMA)&mdash;Institute of Leprosy and other Mycobacterial Diseases, Agra</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Regional Medical Research Centre (RMRC), Bhubaneswar</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Bhopal Memorial Hospital and Research Centre (BMHRC), Bhopal</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 478)</strong></span></span></p>",
    "correct_choice_id": 9326,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2337,
    "choices": [
      {
        "id": 9336,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5000.</span></span></p>"
      },
      {
        "id": 9337,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">30000</span></span></p>"
      },
      {
        "id": 9338,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">100000</span></span></p>"
      },
      {
        "id": 9339,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">200000</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a country with an ongoing effort to control tuberculosis, a public health official is tasked with planning and organizing local TB control efforts in line with the National Tuberculosis Elimination Program (NTEP). A critical aspect of this planning involves understanding the operational capacity of a Tuberculosis Unit (TU) to ensure comprehensive coverage. According to the National Tuberculosis Elimination Program (NTEP), a Tuberculosis Unit is designed to cater to what size of the population?</span></span></p>",
    "unique_key": "Q5344036",
    "question_audio": null,
    "question_video": null,
    "map_id": 34295,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. 200000</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A <strong>major organizational change</strong> in <strong>NTEP</strong> is the <strong>creation of a sub-district level</strong> (Tuberculosis Unit-TU). TUs have been created based on a population -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1 TB unit - 1 per 1.5-2.5 lac population</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1 DMC - 1 per 50000 -1 lac population&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most peripheral unit under RNTCP - DMC&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>DMCs</strong> are manned by a <strong>trained laboratory technician</strong> (LT) of the <strong>State health system</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1 TB unit</strong> (RNTCP) is for a <strong>population of 2.0 Lac</strong> (Range - 1.5 -2.5 lac population)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>RNTCP District microscopic center</strong> is recommended for <strong>50000 - 1 lac population</strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 478)</strong></span></span></p>",
    "correct_choice_id": 9339,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2354,
    "choices": [
      {
        "id": 9404,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Colombo plan</span></span></p>"
      },
      {
        "id": 9405,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">SIDA</span></span></p>"
      },
      {
        "id": 9406,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">WHO</span></span></p>"
      },
      {
        "id": 9407,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">World Bank</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A medical resident is participating in a seminar discussing the various aspects of national tuberculosis control programs. One of the topics under discussion is the funding and support for these programs. The resident is aware that these initiatives are often supported by a combination of domestic and international sources. Which of the following is NOT typically a funding agency for National Tuberculosis Control Programs?</span></span></p>",
    "unique_key": "Q7794296",
    "question_audio": null,
    "question_video": null,
    "map_id": 34303,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Colombo plan.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Colombo Plan 1950</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drawn up for <strong>cooperative economic development</strong> of <strong>South and South East Asia</strong> (20 countries) with the <strong>main aim</strong> of <strong>improving&nbsp;living standards</strong> of people</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Industrial</strong> and <strong>agricultural development</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Support for <strong>Health Promotion</strong> (mostly via fellowships)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">AIIMS, New Delhi was established with financial assistance from New Zealand</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Canada supplied Cobalt therapy units to medical institutions in India</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>National TB Control&nbsp;programmes</strong> are being <strong>assisted</strong> by the following organizations: </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">World Bank <strong>(Option D</strong>)&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Department for International Development (DFID)&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">WHO <strong>(Option C)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Global TB Drug Facility (GDF), </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">United States Agency for International Development (USAID)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">SIDA <strong>(Option B)</strong> </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">DANIDA. </span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>government of India</strong> provides <strong>100 percent grant in- aid</strong> to the <strong>implementing agencies</strong> i.e., states/UTs, besides free drugs.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>programme</strong> is being assisted by the <strong>World Bank and the Department for International Development</strong> (DFID) via WHO. In addition, the <strong>RNTCP</strong> is supported by the <strong>Global TB Drug Facility</strong> (GDF), <strong>Global Fund to Fight AIDS</strong>, <strong>Tuberculosis</strong> and <strong>Malaria</strong> (GFATM), the <strong>United States Agency</strong> for <strong>International Development</strong> (USAID), SIDA and DANIDA. Government of India provides 100 per cent grantin- aid to the implementing agencies i.e., states/UTs, besides free drugs.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 484)</strong></span></span></p>",
    "correct_choice_id": 9404,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2123,
    "choices": [
      {
        "id": 8481,
        "text": "<p><span style=\"font-size:12pt;\">Transition from high birth rate and death rate to low birth and death rate</span></p>"
      },
      {
        "id": 8482,
        "text": "<p><span style=\"font-size:12pt;\">Transition from communicable diseases to non-communicable diseases</span></p>"
      },
      {
        "id": 8483,
        "text": "<p><span style=\"font-size:12pt;\">Transition from High mortality to high morbidity</span></p>"
      },
      {
        "id": 8484,
        "text": "<p><span style=\"font-size:12pt;\">Transition from low sex ratio to high sex ratio</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">While studying population dynamics in a global health lecture, you were asked to describe the term \"Demographic Transition\" as this phenomenon is observed in several countries. Which of the following statements best describes this phenomenon?</span></p>",
    "unique_key": "Q3215998",
    "question_audio": null,
    "question_video": null,
    "map_id": 34324,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. Transition from high birth rate and death rate to low birth and death rate</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Demographic transition</strong> is a <strong>model</strong> used to <strong>explain the process of transition</strong> from <strong>high BR and high DR</strong> (Stage 1 demographic cycle \u2013 High stationary) to <strong>low BR and low DR</strong> (Stage 4 Demographic cycle \u2013 Low stationary) as part of the <strong>economic development</strong></span><br><span style=\"font-size:12pt;\">of a <strong>country</strong> from a <strong>pre-industrial</strong> to an <strong>industrialized economy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/07/20/image-20230720095728-1.png\" width=\"500\" height=\"397\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>India is in Stage III</strong> (Late Expanding Phase) of <strong>Demographic cycle</strong></span><br><span style=\"font-size:12pt;\"><strong>Stage V</strong> (Decline Phase): Germany, Italy, Spain, Portugal, Greece, United Kingdom and Japan (populations are reproducing well &lt; replacement levels)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Demographic transition</strong> is a <strong>model</strong> used to <strong>explain the process of transition</strong> from <strong>high BR</strong> &amp; <strong>DR</strong> to <strong>low BR &amp; DR</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Textbook of community medicine by Sunderlal, 4<sup>th</sup> ed. p76;&nbsp;Park 27/e pg.554</strong></span></p>",
    "correct_choice_id": 8481,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2029,
    "choices": [
      {
        "id": 8109,
        "text": "<p><span style=\"font-size:12pt;\">a-iii, b-i, c-ii, d- iv</span></p>"
      },
      {
        "id": 8110,
        "text": "<p><span style=\"font-size:12pt;\">a-iii, b-ii c-i, d- iv</span></p>"
      },
      {
        "id": 8111,
        "text": "<p><span style=\"font-size:12pt;\">a-iii, b-iv, c-ii, d- i</span></p>"
      },
      {
        "id": 8112,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">a-iii, b-iv, c-i, d- ii</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Match the following programme's (Column A) with the respective ministries (Column B).</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"color:black;font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/13/screenshot-2024-03-13-095743.jpg\" alt=\"\" width=\"700\" height=\"232\"></span></p>",
    "unique_key": "Q7536198",
    "question_audio": null,
    "question_video": null,
    "map_id": 34330,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;A. a-iii, b-i, c-ii, d- iv</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation</u>:</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-111255.png\" alt=\"\" width=\"1000\" height=\"205\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>ICDS programme</strong> -&nbsp;iv. Ministry of Women and Child Development&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective</u>:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ministries to combat malnutrition:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/13/screenshot-2024-03-13-095910.jpg\" alt=\"\" width=\"1000\" height=\"337\"></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 750)</strong></span></p>",
    "correct_choice_id": 8109,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 2032,
    "choices": [
      {
        "id": 8121,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1970</span></span></p>"
      },
      {
        "id": 8122,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1971</span></span></p>"
      },
      {
        "id": 8123,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1972</span></span></p>"
      },
      {
        "id": 8124,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1973</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A public health resident is reviewing the history of health interventions in India and notes a significant reduction in the prevalence of xerophthalmia and child mortality due to vitamin A deficiency after the implementation of a national program. This program was initiated to provide vitamin A supplementation biannually to children aged 6 months to 5 years. In which year was this Vitamin A prophylaxis program launched?</span></span></p>",
    "unique_key": "Q1197736",
    "question_audio": null,
    "question_video": null,
    "map_id": 34331,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. 1970</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Vitamin A prophylaxis programme</strong> was launched by the <strong>Ministry of Health and Family Welfare</strong> in <strong>1970</strong> on the <strong>basis of technology</strong> developed at the <strong>National Institute of Nutrition at Hyderabad</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>WHO recommended strategy</strong> for prevention of <strong>Xerophthalmia</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Short term action: Vitamin-A prophylaxis to vulnerable groups -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-144746.png\" style=\"height:278px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Deworming Program</strong> in <strong>linkage with Vitamin A prophylaxis program</strong>. The dosage&#39;s are -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1&ndash;2 years age</strong>: Half tablet 400 mg Albendazole stat</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>2&ndash;19 years age</strong>: Full tablet 400 mg Albendazole stat</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Vitamin A prophylaxis programme</strong> was launched by the <strong>Ministry of Health</strong> and <strong>Family Welfare in 1970</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 750)</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\">Deworming Program in linkage with Vitamin A prophylaxis program. The dosage&#39;s are -&nbsp;</span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\">1&ndash;2 years age:<strong> Half tablet </strong>400 mg Albendazole stat</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\">2&ndash;19 years age: <strong>Full tablet</strong> 400 mg Albendazole stat</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\">Educational Objective -&nbsp;</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\">Vitamin A prophylaxis programme was launched by the Ministry of Health and Family Welfare in 1970</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><strong>Reference: Park 26<sup>th</sup> edition (page 750)</strong></span></span></p>",
    "correct_choice_id": 8121,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2075,
    "choices": [
      {
        "id": 8293,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1</span></span></p>"
      },
      {
        "id": 8294,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2</span></span></p>"
      },
      {
        "id": 8295,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3</span></span></p>"
      },
      {
        "id": 8296,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In your role as a healthcare planner for a village with a population of 2100 individuals, you are tasked with assessing the need for Anganwadi centers based on national guidelines. Given the current population, how many Anganwadi centers are required in the village as per the norms?</span></span></p>",
    "unique_key": "Q5841787",
    "question_audio": null,
    "question_video": null,
    "map_id": 34315,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;C. 3</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">For <strong>AWCs in rural/urban projects</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1 AWC</strong> for <strong>400-800 population</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>2 AWCs</strong> for <strong>800-1600 population</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>3 AWCs</strong> for <strong>1600-2400 population</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Thereafter, <strong>one AWC</strong> for <strong>multiples of 800 population</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some important Pointers related to Anganwadi -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Heart of ICDS system: Anganwadi</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Focal point for ICDS services delivery is Anganwadi Worker; Each Anganwadi has 1 Anganwadi worker and 1 helper</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1 Anganwadi centre</strong> per <strong>400&ndash;800 population</strong> in <strong>rural and urban area</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1 Anganwadi centre</strong> per <strong>300&ndash;800 population</strong> in <strong>tribal area</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1 Mini-Anganwadi centre</strong> per <strong>150&ndash;400 population</strong> (rural/urban); <strong>150-300</strong> (tribal)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1 Anganwadi on Demand</strong> (AOD) for <strong>settlement &ge; 40 children</strong> under <strong>6 years age</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1 Anganwadi centre</strong> per <strong>400&ndash;800 population</strong> in <strong>rural and urban area</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 680)</strong></span></span></p>",
    "correct_choice_id": 8295,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2079,
    "choices": [
      {
        "id": 8309,
        "text": "<p><span style=\"font-size:12pt;\">600 calories and 12-15 gms of protein</span></p>"
      },
      {
        "id": 8310,
        "text": "<p><span style=\"font-size:12pt;\">600 calories and 20-25 gms of protein</span></p>"
      },
      {
        "id": 8311,
        "text": "<p><span style=\"font-size:12pt;\">800 calories and 12-15 gms of protein</span></p>"
      },
      {
        "id": 8312,
        "text": "<p><span style=\"font-size:12pt;\">800 calories and 20-25 gms of protein</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 2-year-old child with Severe Acute Malnutrition (SAM) has been identified at a local health clinic. As part of the Integrated Child Development Services (ICDS) scheme, you are required to provide supplementary nutrition. According to the ICDS guidelines, what is the recommended supplementary nutrition for a SAM child of this age?</span></p>",
    "unique_key": "Q3065702",
    "question_audio": null,
    "question_video": null,
    "map_id": 34316,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. 800 calories and 20-25 gms of protein&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Severely malnourished child 6-72 months</strong> to get <strong>800 calories</strong> and <strong>20-25 grams protein</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>ICDS</strong> in <strong>India</strong> is <strong>implemented by Ministry of Women</strong> and <strong>Child Development</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Supplemental nutrition given through ICDS</strong>: <strong>300 feeding days</strong> in a <strong>year</strong> [NEW 2014 GUIDELINES]</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Revised norms for free food supplementation under ICDS -&nbsp;</span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-150731.png\" alt=\"\" width=\"1000\" height=\"430\"></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Revised Financial Norms -&nbsp;</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-150825.png\" alt=\"\" width=\"1000\" height=\"239\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Severely malnourished child 6-72 months</strong> to get <strong>800 calories</strong> and <strong>20-25 grams protein</strong>&nbsp;(Revised Financial norm - 12 Rs/day/beneficiary)</span></p><p><span style=\"font-size:12pt;\"><strong>&nbsp;</strong></span></p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 680)</strong></span></p>",
    "correct_choice_id": 8312,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2083,
    "choices": [
      {
        "id": 8325,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">No supplementary nutrition</span></span></p>"
      },
      {
        "id": 8326,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">500 calories and 18-20 gms of protein</span></span></p>"
      },
      {
        "id": 8327,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">600 calories and 18-20 gms of protein</span></span></p>"
      },
      {
        "id": 8328,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">800 calories and 18-20 gms of protein</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">As a physician overseeing nutritional programs at an Integrated Child Development Services (ICDS) center, you are tasked with prescribing supplementary nutrition for pregnant women registered at the center. According to the ICDS guidelines, what is the recommended supplementary nutrition for a pregnant mother?</span></span></p>",
    "unique_key": "Q2807136",
    "question_audio": null,
    "question_video": null,
    "map_id": 34317,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;C. 600 calories and 18-20 gms of protein</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong> &nbsp; &nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Each pregnant</strong> and <strong>nursing woman</strong> to get <strong>600 calories</strong> and <strong>18-20 grams of protein</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>ICDS in India</strong> is implemented by <strong>Ministry of Women</strong> and <strong>Child Development</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Supplemental nutrition given through ICDS</strong>: 300 feeding days in a year [NEW 2014 GUIDELINES]</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Revised norms for free food supplementation under ICDS -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/27/1.jpg\" style=\"height:349px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Revised Financial Norms -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/27/2.jpg\" style=\"height:475px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Each <strong>pregnant</strong> and <strong>nursing woman</strong> to get <strong>600 calories</strong> and <strong>18-20 grams of protein</strong> (Revised Financial norm - 9.5 Rs/day/beneficiary)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26th edition (page 680)</strong></span></span></p>",
    "correct_choice_id": 8327,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2086,
    "choices": [
      {
        "id": 8335,
        "text": "<p><span style=\"font-size:12pt;\">Beti Bachao Beti Padhao</span></p>"
      },
      {
        "id": 8336,
        "text": "<p><span style=\"font-size:12pt;\">Poshan Abhiyan</span></p>"
      },
      {
        "id": 8337,
        "text": "<p><span style=\"font-size:12pt;\">Kishori Shakti Yojana</span></p>"
      },
      {
        "id": 8338,
        "text": "<p><span style=\"font-size:12pt;\">Indira Gandhi Matritva Sahyog Yojana</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">You are conducting a workshop for healthcare workers focusing on adolescent health. One of the initiatives you are discussing is a government scheme aimed at improving the self-development, nutrition, and health status of adolescents. Which scheme specifically addresses these needs?</span></p>",
    "unique_key": "Q1254822",
    "question_audio": null,
    "question_video": null,
    "map_id": 34318,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. Kishori Shakti Yojana</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Kishori Shakti Yojana</strong> (KSY) is being <strong>implemented</strong> using the <strong>infrastructure of ICDS</strong>. The <strong>scheme targets adolescent girls</strong> in the <strong>age group of 11 to 18 years</strong> and <strong>addresses</strong> their <strong>needs of self-development</strong>, <strong>nutrition and health status</strong>, <strong>literacy</strong> and <strong>numerical skills</strong>, <strong>vocational skills</strong> etc.</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>KSY is rename</strong> of \u2018<strong>Adolescent Girl\u2019s Scheme\u2019</strong> under ICDS (Integrated Child Development Services)</span></li><li><span style=\"font-size:12pt;\">Aim of KSY:&nbsp;\u2013 To <strong>improve the nutritional</strong> and <strong>health status</strong> of <strong>adolescent girls</strong></span><ul><li><span style=\"font-size:12pt;\">To promote self-development, awareness of health, hygiene, nutrition, and family life and child care</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Beti Bachao Beti Padhao:&nbsp;</strong> This&nbsp;was <strong>launched on 22 January 2015</strong> by <strong>Prime Minister Narendra Modi</strong>. It <strong>aims to address the issue</strong> of the <strong>declining child sex ratio image</strong> (CSR) and is a <strong>national initiative</strong> jointly run by the&nbsp;<strong>Ministry of Women and Child Development</strong>, the&nbsp;<strong>Ministry of Health</strong> and <strong>Family Welfare&nbsp;and the&nbsp;Ministry of Education</strong>.&nbsp;It mainly targets the clusters in&nbsp;Uttar Pradesh,&nbsp;Haryana,&nbsp;Uttarakhand,&nbsp;Punjab,&nbsp;Bihar&nbsp;and&nbsp;Delhi.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. Poshan Abhiyan:&nbsp;</strong> This was launched by <strong>Hon\u2019ble Prime Minister on 8th March, 2018</strong> in <strong>Jhunjhunu district of Rajasthan</strong>. The <strong>focus of Abhiyaan</strong> is to <strong>lay emphasis on nutritional status of adolescent girls</strong>, <strong>pregnant women</strong>, <strong>lactating mothers</strong> and <strong>children from 0-6 years age.</strong> The programme, through use of technology, convergence and community involvement with a targeted approach strives to reduce the level of stunning, under-nutrition, Anemia and low birth weight in children, as also focus on adolescent girls, pregnant women and lactating mothers, thus holistically addressing malnutrition.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D.&nbsp;Indira Gandhi Matritva Sahyog Yojana: </strong>Renamed as&nbsp;<strong>Pradhan Mantri Matru Vandana Yojana</strong> (PMMVY) in <strong>2017</strong>,&nbsp;The scheme is implemented by the&nbsp;<strong>Ministry of Women and Child Development</strong>. It is a&nbsp;conditional cash transfer&nbsp;scheme for pregnant and lactating women of 19 years of age or above for the first live birth.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Kishori Shakti Yojana</strong> (KSY)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Interventions:&nbsp;</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12pt;\"><strong>Adolescent girls Scheme-I</strong> - \u2018Girl-to-girl Approach\u2019 (11 \u2013 15 years old girls)</span></li><li><span style=\"font-size:12pt;\"><strong>Adolescent girls scheme-II</strong> -&nbsp;\u2018Balika Mandals\u2019 (11 \u2013 18 years old girls)&nbsp;</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Activities:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Preventive health, hygiene &amp; nutrition education&nbsp;</span></li><li><span style=\"font-size:12pt;\">Working on Anganwadi centre</span></li><li><span style=\"font-size:12pt;\">Family life education</span></li><li><span style=\"font-size:12pt;\">Participate in creative activities</span></li><li><span style=\"font-size:12pt;\">Skill development or vocational training</span></li><li><span style=\"font-size:12pt;\">Learn about significance of education &amp; life skills, personal hygiene, environmental sanitation, nutrition, home nursing, first aid, communicable diseases, VPDs, family life, child care and development, constitutional rights &amp; their impact on quality of life</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 681)</strong></span></p>",
    "correct_choice_id": 8337,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2104,
    "choices": [
      {
        "id": 8405,
        "text": "<p><span style=\"font-size:12pt;\">Village panchayat</span></p>"
      },
      {
        "id": 8406,
        "text": "<p><span style=\"font-size:12pt;\">Health sub centre</span></p>"
      },
      {
        "id": 8407,
        "text": "<p><span style=\"font-size:12pt;\">Community health centre</span></p>"
      },
      {
        "id": 8408,
        "text": "<p><span style=\"font-size:12pt;\">Community development block</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">As part of your administrative duties in overseeing a rural healthcare delivery system, you need to familiarize yourself with the structural units of the Integrated Child Development Services (ICDS). Which of the following is the primary administrative unit of ICDS in a rural area?</span></p>",
    "unique_key": "Q4722527",
    "question_audio": null,
    "question_video": null,
    "map_id": 34320,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;D. Community development block</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u>&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>An administrative unit of ICDS</strong>:</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Community Development Block</strong> - each project covering a population of 1,00,000 (rural/urban) or 35,000 (tribal)</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>1 CDPO</strong> (Community Development Project Officer) is <strong>in charge of 4 supervisors</strong> (Mukhyasevikas) and <strong>100 Anganwadis</strong> (each supervisor for 25 Anganwadis)</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>ICDS</strong> is <strong>one of the world\u2019s largest programs</strong> for <strong>early childhood development</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>ICDS</strong> is a <strong>centrally sponsored scheme</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>ICDS</strong> provides an <strong>integrated package of services</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Supplementary nutrition</span></li><li><span style=\"font-size:12pt;\">Immunization</span></li><li><span style=\"font-size:12pt;\">Health check-up</span></li><li><span style=\"font-size:12pt;\">Medical referral services</span></li><li><span style=\"font-size:12pt;\">Nutrition and health education for women</span></li><li><span style=\"font-size:12pt;\">Non-formal education for children aged 3 \u2013 6 years, and pregnant and nursing mothers in rural, urban and tribal areas</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>ICDS Beneficiaries</strong> (Irrespective of income of family) -&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Children 0 \u2013 6 years age</span></li><li><span style=\"font-size:12pt;\">Pregnant and lactating mothers</span></li><li><span style=\"font-size:12pt;\">Women in reproductive age group</span></li><li><span style=\"font-size:12pt;\">Adolescent girls 11 \u2013 18 years</span></li><li><span style=\"font-size:12pt;\"><strong>Heart of ICDS system</strong>: <strong>Anganwadi</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Focal point for ICDS services delivery</strong> is <strong>Anganwadi Worker</strong>; Each Anganwadi has 1 Anganwadi worker and 1 helper</span><ul><li><span style=\"font-size:12pt;\">1 Anganwadi centre per 400\u2013800 population in rural and urban projects</span></li><li><span style=\"font-size:12pt;\">1 Anganwadi centre per 300\u2013800 population in tribal projects</span></li><li><span style=\"font-size:12pt;\">1 Mini-Anganwadi centre per 150\u2013400 population (rural &amp; urban); 150-300 (tribal)</span></li><li><span style=\"font-size:12pt;\">1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Administrative unit of ICDS in a rural area</strong> -&nbsp;Community Development Block [100,000 population&nbsp;(rural/urban) or 35,000 (tribal)]</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 681)</strong></span></p>",
    "correct_choice_id": 8408,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2109,
    "choices": [
      {
        "id": 8425,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1951</span></span></p>"
      },
      {
        "id": 8426,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1961</span></span></p>"
      },
      {
        "id": 8427,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1971</span></span></p>"
      },
      {
        "id": 8428,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1995</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In an effort to enhance the understanding of public health nutrition programs among your medical students, you&#39;re covering the history of such initiatives in India. Can you recall the year in which the Mid-day Meal Programme, aimed at improving the nutritional status of school-age children, was launched?</span></span></p>",
    "unique_key": "Q4472669",
    "question_audio": null,
    "question_video": null,
    "map_id": 34321,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;B. 1961&nbsp;&nbsp; </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>Mid-day Meal Programme</strong> (MDMP) is also known as <strong>School Lunch Programme</strong>. This <strong>programme</strong> has been in <strong>operation since 1961</strong> throughout the country.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mid-day Meal Programme</strong> (MDMP)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>The major objective of MDMP</strong>: To <strong>attract more children for admission</strong> to schools and retain them so that literacy improvement of children could be brought about.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>meal is a supplement</strong> and not a substitute to the home diet</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>meal should supply 1/3 of the total energy requirement</strong> and <strong>1/2 of the total protein requirement.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MDMP</strong> is being <strong>operationalized</strong> under the <strong>Ministry of Human&nbsp;Resource</strong> &amp; <strong>Development</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">National Institute of Nutrition, Hyderabad is of the view that minimum number of feeding days in year be 250 to have the desired impact on children</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mid-day Meal Scheme</strong> (MDMS) (National Programme of Nutritional Support to Primary Education): <strong>Launched in 1995</strong> with the <strong>main objective universalization</strong> of <strong>primary education</strong> by <strong>increasing enrolment</strong>, <strong>retention</strong> and <strong>attendance</strong> and simultaneously impacting on the nutrition of students in primary classes.&nbsp;It aims at providing 450&ndash;700 calories and 12&ndash;20 gm proteins per day to all children class I to VIII.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Principles for formulating mid-day meals</strong>:</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meal should be a supplement only not a substitute for home diet</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meal should provide 1/3 calories and 1/2 proteins</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meal cost should be low</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Complicated cooking process must not be involved</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Use locally available foods</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Keep changing menu frequently</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A model menu for mid-day school meal</strong>:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-151658.png\" style=\"height:314px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mid-day Meal Programme</strong> (MDMP) or&nbsp;<strong>School Lunch Programme</strong> launched in&nbsp;<strong>1961</strong>,&nbsp;under the <strong>Ministry of Human&nbsp;Resource</strong> &amp; <strong>Development</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Midday meal program provides - 1/3 calories and 1/2 proteins.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Amount of cereals in Mid-day meal program 100 grams</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 751)</strong></span></span></p>",
    "correct_choice_id": 8426,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2112,
    "choices": [
      {
        "id": 8437,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1951</span></span></p>"
      },
      {
        "id": 8438,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1961</span></span></p>"
      },
      {
        "id": 8439,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1971</span></span></p>"
      },
      {
        "id": 8440,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1995</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a community health class, you are discussing various health and educational interventions in India. You want the class to understand the intent behind the Mid-Day Meal Scheme. This scheme was primarily launched with the objective to reduce school dropouts and to provide basic education for all. In which year was the Mid-Day Meal Scheme initiated?</span></span></p>",
    "unique_key": "Q3103961",
    "question_audio": null,
    "question_video": null,
    "map_id": 34322,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. 1995</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mid-day meal scheme</strong> is also known as <strong>National Programme of Nutritional Support</strong> to <strong>Primary Education</strong>. It was launched as a <strong>centrally sponsored scheme on 15<sup>th</sup> August 1995</strong> and <strong>revised in 2004</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mid-day Meal Scheme</strong> (MDMS) (National Programme of Nutritional Support to Primary Education): <strong>Launched in 1995</strong> with the main objective <strong>universalization of primary education</strong> by <strong>increasing enrolment</strong>, <strong>retention</strong> and <strong>attendance</strong> and <strong>simultaneously impacting</strong> on the <strong>nutrition of students</strong> in <strong>primary classes</strong>.&nbsp;It aims at providing 450&ndash;700 calories and 12&ndash;20 gm proteins per day to all children class I to VIII.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Principles for formulating mid-day meals</strong>:</span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meal should be a supplement only not a substitute for home diet</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meal should provide 1/3 calories and 1/2 proteins</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meal cost should be low</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Complicated cooking process must not be involved</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Use locally available foods</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Keep changing menu frequently</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A model menu for mid-day school meal:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-151942.png\" style=\"height:305px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mid-day Meal Scheme</strong> launched in&nbsp;<strong>1995</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meal should provide - <strong>1/3 calories and 1/2 proteins</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 751)</strong></span></span></p>",
    "correct_choice_id": 8440,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2119,
    "choices": [
      {
        "id": 8465,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fortification of essential foods</span></span></p>"
      },
      {
        "id": 8466,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Popularization of low-cost nutritious food</span></span></p>"
      },
      {
        "id": 8467,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Control of micronutrient deficiency</span></span></p>"
      },
      {
        "id": 8468,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Nutritional surveillance</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While reviewing the National Nutrition Policy of 1993 with your students, you want them to differentiate between direct or short-term and indirect or long-term interventions. Which of the following would NOT be considered a direct or short-term intervention according to the National Nutrition Policy of 1993?</span></span></p>",
    "unique_key": "Q8100866",
    "question_audio": null,
    "question_video": null,
    "map_id": 34323,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans.&nbsp;D. Nutritional surveillance</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nutritional Surveillance</strong> -&nbsp;Keeping a <strong>watch over nutrition</strong>, in order to <strong>make decisions</strong> that will <strong>lead to improvement in nutrition</strong> of the <strong>population</strong>. The main strategy is the <strong>Detection of malnutrition</strong> (nutritional survey).&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Approach</strong>: Diagnostic-interventional</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Sample</strong>: Representative, 50 - 100 size group</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Objectives</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">To aid <strong>health and development</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">To provide <strong>input for program management</strong> and <strong>evaluation</strong> (to policy makers)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">To give <strong>timely warning</strong> and <strong>intervention</strong> (to prevent short-term food crises).</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">All <strong>3 options</strong> are considered as a <strong>direct or short-term intervention</strong> according to the <strong>National Nutrition Policy of 1993</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">National Nutrition Policy, 1993</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>National Nutrition Policy</strong> (India) was introduced in <strong>1993 to combat</strong> the <strong>problem of undernutrition</strong>. It aims to address this problem by utilising direct (short term) and indirect (long term) interventions.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Direct intervention - Short-term</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Nutrition interventions for especially vulnerable groups.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fortification of essential foods. (Option A)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Popularization of low-cost nutritious food. (Option B)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Control of micro-nutrient deficiencies among vulnerable groups. (Option C)</span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>National Nutrition Policy</strong> (India) was introduced in <strong>1993 to combat the problem of undernutrition</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Direct short term intervention</strong> -&nbsp;Nutrition interventions for especially vulnerable groups;&nbsp;Fortification of essential foods;&nbsp;Popularization of low-cost nutritious food;&nbsp;Control of micro-nutrient deficiencies among vulnerable groups<strong>.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 749)</strong></span></span></p>",
    "correct_choice_id": 8468,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2145,
    "choices": [
      {
        "id": 8569,
        "text": "<p><span style=\"font-size:12pt;\">10 ppm</span></p>"
      },
      {
        "id": 8570,
        "text": "<p><span style=\"font-size:12pt;\">15 ppm</span></p>"
      },
      {
        "id": 8571,
        "text": "<p><span style=\"font-size:12pt;\">30 ppm</span></p>"
      },
      {
        "id": 8572,
        "text": "<p><span style=\"font-size:12pt;\">50 ppm</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">As you prepare for a community health lecture on micronutrient deficiencies, you plan to highlight the critical standards set by public health initiatives. According to the guidelines of the National Iodine Deficiency Disorder Control Programme (NIDDCP), what is the recommended level of iodine content in salt at the consumption level?</span></p>",
    "unique_key": "Q6529086",
    "question_audio": null,
    "question_video": null,
    "map_id": 34325,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. 15 ppm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Standards of Iodised salt</strong>&nbsp;(Level of Iodization in salt)&nbsp;as per <strong>National Iodine Deficiency Disorder Control Programme</strong> (NIDDCP)-&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">At production level: 30 ppm</span></li><li><span style=\"font-size:12pt;\">At consumer level: 15 ppm.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Some important Pointers related to NIDDCP</strong> -&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Iodine deficiency</strong> as a major <strong>public health problem</strong> - if&nbsp;<strong>Goitre prevalence &gt; 10%</strong></span></li><li><span style=\"font-size:12pt;\">Daily requirement of Iodine: 150 mcg (&lt;1 teaspoon over lifetime) supplied normally by well-balanced diets and drinking water</span></li><li><span style=\"font-size:12pt;\">WHO/UNICEF/ICCIDD recommended daily iodine intake -&nbsp;</span></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-152829.png\" alt=\"\" width=\"1000\" height=\"173\"></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Level of iodine</strong> content of <strong>salt at consumption level</strong> - <strong>15 ppm</strong> and at <strong>production level 30 ppm</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>\u200b\u200b\u200b\u200b\u200b\u200b\u200b<u>Ref</u>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 560)</strong></span></p>",
    "correct_choice_id": 8570,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2154,
    "choices": [
      {
        "id": 8605,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Codex Alimentarius</span></span></p>"
      },
      {
        "id": 8606,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">PFA standards</span></span></p>"
      },
      {
        "id": 8607,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Agmark Standards</span></span></p>"
      },
      {
        "id": 8608,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Bureau of Indian Standards</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A dietician at a public hospital in India is reviewing the guidelines to ensure the food provided meets the regulatory requirements. She understands that there are specific standards set to achieve a minimum level of quality for foodstuffs under Indian conditions. These standards, known for their rigorous testing and quality assurance, are critical in preventing foodborne illnesses. Which of the following represents these standards?</span></span></p>",
    "unique_key": "Q4793289",
    "question_audio": null,
    "question_video": null,
    "map_id": 34328,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;B. PFA standards</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Under the Prevention of Food Adulteration Act</strong> (1954) standards have been established which are revised from time to time by the <strong>&ldquo;Central Committee for Food Standards&quot;.</strong> The purpose of the <strong>PFA standards</strong> is to obtain a <strong>minimum level of quality of foodstuffs</strong> attainable under <strong>Indian conditions</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Codex Alimentarius: Joint FAO/WHO standards</strong> for <strong>international markets</strong>; Food standards in India are based on <strong>Codex Alimentarius</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Agmark standards: Purely voluntary</strong>; express degree of excellence above PFA standards.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Bureau of Indian Standards: Purely voluntary</strong>; express degree of excellence above PFA standards</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>FOOD SAFETY AND STANDARDS AUTHORITY OF INDIA</strong> (FSSAI)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Background</strong>: Established under Food Safety and Standards Act, 2006</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Head office</strong>: New Delhi</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Function</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Single reference point for all matters relating to food safety and standards</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Establishment of the Authority</strong>: Ministry of Health &amp; Family Welfare, Government of India is the Administrative Ministry for the implementation of FSSAI</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 749)</strong></span></span></p>",
    "correct_choice_id": 8606,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2166,
    "choices": [
      {
        "id": 8653,
        "text": "<p><span style=\"font-size:12pt;\">1950</span></p>"
      },
      {
        "id": 8654,
        "text": "<p><span style=\"font-size:12pt;\">1954</span></p>"
      },
      {
        "id": 8655,
        "text": "<p><span style=\"font-size:12pt;\">1960</span></p>"
      },
      {
        "id": 8656,
        "text": "<p><span style=\"font-size:12pt;\">1964</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt;\">A policy advisor is consulting with a team of public health officials on the historical legal framework for food safety in India. They are reviewing past legislation to understand how food quality standards have evolved. The advisor asks the team to identify the year in which the Prevention of Food Adulteration Act, a pivotal health mandate aimed at addressing food adulteration, was enacted. Which year did this legislative action take place?</span></p>",
    "unique_key": "Q2814060",
    "question_audio": null,
    "question_video": null,
    "map_id": 34333,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;B. 1954</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Enacted</strong> by the <strong>Indian Parliament in 1954</strong>, with the objective of <strong>ensuring pure and wholesome food</strong> to the <strong>consumers</strong> and to <strong>protect them from fraudulent</strong> and <strong>deceptive trade practices</strong>, the <strong>Prevention of Food Adulteration</strong> (PFA) <strong>Act</strong> was <strong>amended</strong> in <strong>1964, 1976</strong> and lately in <strong>1986</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Some important pointers related to PFA</strong> -&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">According to <strong>Prevention of Food Adulteration</strong> (PFA) <strong>Act 1954</strong>: \u2013 <strong>Level of iodisation</strong> in <strong>salt is&nbsp;30 ppm</strong> at <strong>production level</strong> and <strong>15 ppm</strong> at <strong>consumer level</strong></span></li><li><span style=\"font-size:12pt;\">PFA standards: Laid under \u2018Prevention of Food Adulteration Act 1954\u2019; to obtain a <strong>minimum level of quality of food</strong> stuffs attainable under Indian conditions</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 748)</strong></span></p>",
    "correct_choice_id": 8654,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2171,
    "choices": [
      {
        "id": 8673,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hazard Analysis and Critical Control Points</span></span></p>"
      },
      {
        "id": 8674,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Health Analysis and Critical Control Points</span></span></p>"
      },
      {
        "id": 8675,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hazard Analysis and Critical Care Points</span></span></p>"
      },
      {
        "id": 8676,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Health Analysis and Critical Care Points</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A food safety officer is conducting a training session on food safety protocols as mandated by the Food Safety and Standards Authority of India (FSSAI). She emphasizes a particular systematic approach that the FSSAI encourages for identifying and controlling hazards throughout the food chain. What does the acronym HACCP, as endorsed by FSSAI, stand for?</span></span></p>",
    "unique_key": "Q8717559",
    "question_audio": null,
    "question_video": null,
    "map_id": 34334,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Hazard Analysis and Critical Control Points</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Hazard Analysis</strong> and <strong>Critical Control Points</strong> (HACCP) is the <strong>cornerstone of FSSAI</strong>.&nbsp;<strong>HACCP</strong> is a <strong>structured approach</strong> that <strong>focuses on identifying potential food safety hazards</strong> and <strong>establishing critical control points</strong> to <strong>prevent, eliminate</strong>, or <strong>reduce these hazards</strong> to an <strong>acceptable level</strong>, which is critical for maintaining food safety standards.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>HACCP</strong> is a <strong>systematic preventive approach</strong> to <strong>food safety</strong>, <strong>focusing</strong> on the <strong>identification</strong> and <strong>control of hazards</strong> throughout the <strong>food chain</strong>, a process endorsed by the FSSAI.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">HACCP - Hazard Analysis and Critical Control Points</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: https://foodregulatory.fssai.gov.in/HACCP-certification</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>",
    "correct_choice_id": 8673,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2176,
    "choices": [
      {
        "id": 8693,
        "text": "<p><span style=\"font-size:12pt;\">Phosphatase test</span></p>"
      },
      {
        "id": 8694,
        "text": "<p><span style=\"font-size:12pt;\">Standard plate count</span></p>"
      },
      {
        "id": 8695,
        "text": "<p><span style=\"font-size:12pt;\">Coliform count</span></p>"
      },
      {
        "id": 8696,
        "text": "<p><span style=\"font-size:12pt;\">Paper chromatography test</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A medical resident is rotating in a public health department and is reviewing the quality control measures for pasteurized milk. Which of the following is NOT a standard test for assessing the quality of pasteurized milk?</span></p>",
    "unique_key": "Q6654709",
    "question_audio": null,
    "question_video": null,
    "map_id": 34311,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;D. Paper chromatography test</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Paper chromatography test: This is used to <strong>detect&nbsp;Argemone oil</strong> (Sanguinarine toxin). The most <strong>sensitive test to diagnose Epidemic Dropsy</strong>, NOT the quality of pasteurized milk.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Effect/sufficiency/adequacy of pasteurization is assessed by \u2013</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Phosphatase test (MC):</strong> This test is widely used to <strong>check the efficiency</strong> of <strong>pasteurization</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Standard plate count:</strong> The <strong>bacteriological quality</strong> of <strong>pasteurized milk</strong> is determined by the <strong>standard plate count</strong>.&nbsp;Enforced limit is 30,000 bacterial count per ml of pasteurized milk</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Coliform count:</strong> Coliform organisms are usually <strong>completely destroyed</strong> by <strong>pasteurization</strong>, and therefore, their <strong>presence in pasteurized milk</strong> is an indication either of <strong>improper pasteurization</strong> or <strong>post-pasteurization contamination</strong>.&nbsp;Standard is coliforms be absent in 1 ml of milk</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Some important pointers related to Pasteurization -&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Pasteurization of milk is a type of - Primary prevention</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Chemical Disinfectants -&nbsp;Pasteurization (70\u00b0 Celsius for 30 minutes for pathogenic microorganisms except spores)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Effect</strong>/<strong>sufficiency</strong>/<strong>adequacy of pasteurization</strong> of <strong>Milk is assessed</strong> by \u2013&nbsp;<strong>Phosphatase test</strong> (MC used test).&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Methods of Pasteurization -&nbsp;</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-153823.png\" alt=\"\" width=\"1000\" height=\"401\"></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 745)</strong></span></p>",
    "correct_choice_id": 8696,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2182,
    "choices": [
      {
        "id": 8717,
        "text": "<p><span style=\"font-size:12pt;\">a- i, b- ii, c-iii</span></p>"
      },
      {
        "id": 8718,
        "text": "<p><span style=\"font-size:12pt;\">a- iii, b- i, c-ii</span></p>"
      },
      {
        "id": 8719,
        "text": "<p><span style=\"font-size:12pt;\">a- ii, b- iii, c-i</span></p>"
      },
      {
        "id": 8720,
        "text": "<p><span style=\"font-size:12pt;\">a- ii, b- i, c-iii</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A medical resident is studying the effects of various natural toxins on human health. Match the following toxins with the diseases they are commonly associated with:</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture48.jpg\" alt=\"\" width=\"600\" height=\"334\"></p>",
    "unique_key": "Q4875304",
    "question_audio": null,
    "question_video": null,
    "map_id": 34312,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;D. a- ii, b- i, c-iii</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The cause of <strong>Nuerolathyrism is a toxin</strong>, <strong>Beta oxalyl amino alanine</strong> (BOAA) which is found in the <strong>seeds of the pulse</strong>, <strong>L.sativus</strong> (Khesari dhal).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Epidemic dropsy</strong>-<i> </i>sanguinarine from argemone oil This toxic substance interferes with the oxidation of pyruvic acid which accumulates in the blood.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Endemic ascites</strong>- pyrrolizidine alkaloids in Jhunjhunia seeds were found to be hepatotoxins.</span></p><p><span style=\"font-size:12pt;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></p><p><span style=\"font-size:12pt;\"><strong>Lathyrism</strong> -&nbsp;<strong>Neurolathyrism</strong> is caused by eating the pulse <strong>\u2018Khesari Dal</strong> (Lathyrus sativus)\u2019. Diets containing over 30% of this dal consumed over a period of 2 - 6 months result in neurolathyrism.&nbsp;Toxin is present in lathyrus seeds is Beta oxalyl amino alanine (BOAA).&nbsp;It manifests as following stages:&nbsp;Latent stage;&nbsp;No-stick stage;&nbsp;One-stick stage;&nbsp;Two-stick stage and&nbsp;Crawler stage.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Interventions for prevention and control of lathyrism</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Vitamin C prophylaxis</span></li><li><span style=\"font-size:12pt;\">Banning the crop</span></li><li><span style=\"font-size:12pt;\">Removal of toxin: Steeping method and Parboiling</span></li><li><span style=\"font-size:12pt;\">Education</span></li><li><span style=\"font-size:12pt;\">Genetic approach</span></li><li><span style=\"font-size:12pt;\">Socio-economic changes</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Epidemic Dropsy</strong>&nbsp;\u2013 This is caused by <strong>contamination of mustard oil with \u2018Argemone oil\u2019</strong>.&nbsp;Toxin \u2018Sanguinarine\u2019 is contained in argemone oil. It may lead to sudden noninflammatory edema of bilateral lower limbs, diarrhea, dyspnoea, cardiac failure and death; It can also lead to glaucoma; It may sometimes manifest as \u2018Sarcoids\u2019 (dilatation of skin capillaries).&nbsp;Epidemic dropsy may occur in all ages except breast-fed infants.\u200b\u200b\u200b\u200b\u200b\u200b&nbsp;Edema in Epidemic dropsy occurs due to proteinuria (specifically loss of albumin).</span></p><p><br><span style=\"font-size:12pt;\">Argemone oil may be detected by following tests:&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Nitric acid test</span></li><li><span style=\"font-size:12pt;\"><strong>Paper chromatography test</strong>: Most <strong>sensitive test</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Endemic Ascites</strong>:&nbsp;</span></p><p><br><span style=\"font-size:12pt;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Toxin</strong>: Pyrrolizidine alkaloids (Hepatotoxins)</span><br><span style=\"font-size:12pt;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adulterant</strong>: Crotalaria plant (Jhunjhunia)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-154238.png\" alt=\"\" width=\"1000\" height=\"309\"></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 746, 747)</strong></span></p>",
    "correct_choice_id": 8720,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 2191,
    "choices": [
      {
        "id": 8753,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Nitric acid test</span></span></p>"
      },
      {
        "id": 8754,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Methylene blue test</span></span></p>"
      },
      {
        "id": 8755,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Phosphatase test</span></span></p>"
      },
      {
        "id": 8756,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Paper chromatography test</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A physician is investigating a cluster of epidemic dropsy cases in a community. The common link appears to be the consumption of mustard oil, which may be contaminated with argemone oil. Which test is most sensitive for the detection of argemone oil contamination in food products?</span></span></p>",
    "unique_key": "Q7540663",
    "question_audio": null,
    "question_video": null,
    "map_id": 34313,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;D. Paper chromatography test</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Paper chromatography test</strong>: This is the most <strong>sensitive test</strong> yet devised. It can detect <strong>argemone oil</strong> up to <strong>0.0001 percent in all edible oils and fats</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Argemone oil</strong> may be detected by following tests&nbsp;&ndash; <strong>Nitric acid test</strong> and&nbsp;<strong>Paper chromatography test</strong> (Most sensitive test)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Nitric acid test:</strong> It can <strong>detect contamination of mustard oil with argemone oil</strong>, but not as sensitive as Paper Chromatography test</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Methylene blue test:</strong>&nbsp;An <strong>indirect method</strong> for <strong>detection of microorganisms</strong> in <strong>milk</strong> (Test for Contamination of milk)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Phosphatase test:</strong> Widely used test for <strong>Pasteurized Milk</strong> to check <strong>adequacy/sufficiency of pasteurization</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Epidemic Dropsy</strong> -&nbsp;Is caused by <strong>contamination of mustard oil</strong> with <strong>&lsquo;Argemone oil&rsquo;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Toxin</strong>: <strong>&lsquo;Sanguinarine&rsquo;</strong> is the <strong>toxin contained in argemone oil</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mechanism - Sanguinarine interferes with oxidation of &lsquo;pyruvic acid&rsquo;, which accumulates in blood: It may lead to sudden non-inflammatory edema of bilateral lower limbs, diarrhea, dyspnoea, cardiac failure and death; It can also lead to glaucoma; It may sometimes manifest as &lsquo;Sarcoids&rsquo; (dilatation of skin capillaries).&nbsp;</span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Epidemic dropsy may occur in all ages except breast-fed infants</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The mortality of epidemic dropsy varies from 5 to 50%</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Edema in Epidemic dropsy occurs due to proteinuria (specifically loss of albumin).</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Paper chromatography test</strong> as the most <strong>sensitive method</strong> for <strong>detecting argemone oil</strong> (toxin Sanguinarine) contamination in food products.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 747)</strong></span></span></p>",
    "correct_choice_id": 8756,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2198,
    "choices": [
      {
        "id": 8781,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fluoridation of water</span></span></p>"
      },
      {
        "id": 8782,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Iodization of salt</span></span></p>"
      },
      {
        "id": 8783,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Vitamin D in milk</span></span></p>"
      },
      {
        "id": 8784,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Vanaspati in Ghee</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">During a public health seminar on nutrition, a presentation is given on the various methods used to combat micronutrient deficiencies in populations. One method discussed is food fortification. Which of the following is NOT an example of food fortification?</span></span></p>",
    "unique_key": "Q3985560",
    "question_audio": null,
    "question_video": null,
    "map_id": 34314,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. Vanaspati in Ghee</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mixing of Vanaspati in Ghee</strong> is <strong>food adulteration</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Example of fortification of food or water.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Fluoridation of water </strong>as a <strong>prevention</strong> of <strong>dental caries</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Iodization of salt </strong>for <strong>combating the problem</strong> of <strong>endemic goitre</strong> (According to Prevention of Food Adulteration (PFA) Act&rsquo; 1954.<strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Level of iodisation </strong>- Minimum 30 ppm at production level and 15 ppm at consumer level;&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Moisture content</strong>: &lt; 6.0% by weight;&nbsp;Sodium chloride: &gt; 96.0% by weight.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Vitamin D in milk:&nbsp;Food fortification</strong> (e.g., vanaspati, milk) with <strong>vitamins A</strong> and <strong>D</strong> (2500 IU Vitamin A and 175 IU Vitamin D&nbsp;per 100 grams).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Food fortification</strong>: Is a <strong>public health</strong>, measure where <strong>nutrients are added to food</strong> (in relatively small quantities), to <strong>maintain/improve the quality of diet</strong> of a <strong>group</strong>, <strong>community</strong> or a population. Food Fortification is an example of <strong>&lsquo;Primary Level of Prevention&rsquo;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Examples of fortification of food or water are</strong> -&nbsp;&nbsp;Fluoridation of water;&nbsp;Iodization of salt;&nbsp;vanaspati ghee with vitamins A and D</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Food Adulteration diseases -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-154814.png\" style=\"height:315px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 748)</strong></span></span></p>",
    "correct_choice_id": 8784,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2231,
    "choices": [
      {
        "id": 8913,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Article 366</span></span></p>"
      },
      {
        "id": 8914,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Article 322</span></span></p>"
      },
      {
        "id": 8915,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Article 360</span></span></p>"
      },
      {
        "id": 8916,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Article 320</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While preparing for a public health policy exam, a medical student needs to cite the article from the Indian Constitution that defines &quot;Scheduled Tribes&quot; for her thesis on healthcare disparities. Which article of the Indian Constitution should she refer to for the accurate definition of &quot;Scheduled Tribes&quot;?</span></span></p>",
    "unique_key": "Q9401432",
    "question_audio": null,
    "question_video": null,
    "map_id": 34319,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;A. Article 366</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The term <strong>Scheduled Tribes</strong> first appeared in the <strong>constitution of India</strong>. <strong>Article 366</strong> defined <strong>scheduled tribes</strong> as <strong>&ldquo;such tribes or tribal communities or parts of or groups within such tribes or tribal communities as are deemed under Article 342 to be Scheduled Tribes for the purpose of this constitution&rdquo;.</strong> The list is state/UT specific and a community declared as a scheduled tribe in one state need not be so in another state.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Article 322: &nbsp;</strong>The <strong>expenses</strong> of the <strong>Union or a State Public Service Commission</strong>, including any <strong>salaries</strong>, <strong>allowances</strong> and <strong>pensions</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Article 360: &nbsp;</strong>This article&nbsp;gives the <strong>President the authority</strong> to declare a <strong>financial emergency</strong> in the <strong>country</strong> if there is a threat to India&#39;s financial stability or credit.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Article 320: &nbsp;</strong>Functions of <strong>Public Service Commissions</strong> (Union and State) like to <strong>conduct examinations</strong> for appointments to the services.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Scheduled Tribes</strong> [Article 366 (25)] -&nbsp;Includes <strong>tribes or communities</strong> as deemed under <strong>Article 342</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Other Important Articles -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Article 21</strong> -&nbsp;<strong>Right to life</strong> of citizens of India</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Article 24</strong> - <strong>Article of child rights</strong> - Prohibits employment of children below 14 years in factories;&nbsp;Prevents abuse of children at tender age&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Article 45</strong> - Provides for <strong>free and compulsory education</strong> for all children till 14 years of age.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 795)</strong></span></span></p>",
    "correct_choice_id": 8913,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2276,
    "choices": [
      {
        "id": 9093,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">\u200b\u200b\u200b\u200b\u200b\u200bA drug/medicine is counterfeit if it is produced with an intention to cheat.</span></span></p>"
      },
      {
        "id": 9094,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Includes mis-labelling, absence of active ingredients, a wrong ingredient, or the correct ingredient in an insufficient quantity.</span></span></p>"
      },
      {
        "id": 9095,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Only generic products can be counterfeited.</span></span></p>"
      },
      {
        "id": 9096,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Anti-malarial are amongst the most commonly reported sub-standard and falsified medical products.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old male with a history of hypertension presents to your clinic. He reports that he has been compliant with his medication regimen but has recently been experiencing a return of his symptoms of high blood pressure. Upon further investigation, you discover that he purchased his medication from an online source that is not associated with a licensed pharmacy. This raises your concern about the authenticity of his medication. Which of the following statements is incorrect about counterfeit medicines?</span></span></p>",
    "unique_key": "Q3117949",
    "question_audio": null,
    "question_video": null,
    "map_id": 34326,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. &nbsp;Only generic products can be counterfeited.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The statement is incorrect, as <strong>both branded</strong> and <strong>generic products</strong> can be <strong>counterfeited</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>COUNTERFEIT MEDICINES:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">WHO definition: A <strong>drug/medication</strong> which is produced with <strong>intention to cheat</strong></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mislabelling (including fudging expiry date)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">No active ingredients</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Wrong ingredient</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Right ingredient in insufficient quantity</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Types of counterfeit medicines</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In developed countries: <strong>New expensive lifestyle medicines</strong> (hormones, steroids, antihistamines)</span></span>\r\n\t\t<ul>\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In developing countries: <strong>Medications to treat life-threatening&nbsp;conditions</strong> (HIV/AIDS, TB, Malaria)</span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Global burden</strong>: More than 10% of global medicines and 25% of medicines in developing countries</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>According to WHO&rsquo;s definition, a drug/medicine is counterfeit if - </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. </strong>It is produced with an <strong>intention to cheat </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. </strong>This can include <strong>mis-labelling</strong> (including fudging expiry date), or <strong>no active ingredients,</strong> a wrong ingredient, or the correct ingredient in an insufficient quantity </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Anti-malarial</strong> and <strong>antibiotics</strong> are amongst the <strong>most commonly reported sub-standard</strong> and <strong>falsified medical products</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>QUALITY CONTROL IN DRUG SECTOR IN INDIA</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Quality control of drugs in India:</span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drugs and Cosmetics Act 1940</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drugs and Cosmetics Rules 1945</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Central Drugs Standard Control Organisation</strong> (CDSCO): &ndash; Headed by:<br />\r\n\t1. Central level: Drugs Controller General, India (DGHS, MOHFW)<br />\r\n\t2. State level: State Drugs Controllers</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Main functions:</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. Quality control of imported drugs<br />\r\n2. Coordination of activities under State Drugs Control Authorities<br />\r\n3. Approval for importation/manufacture of new drugs<br />\r\n4. Laying standards for and act as &lsquo;Central Licensing Authority for blood and blood products, iv fluids, sera, vaccines, r-DNA products&rsquo;</span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Zonal offices: Mumbai, Kolkata, Ghaziabad, Chennai.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26th edition (page 550)</strong></span></span></p>",
    "correct_choice_id": 9095,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2279,
    "choices": [
      {
        "id": 9105,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">321 drugs</span></span></p>"
      },
      {
        "id": 9106,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">309 drugs</span></span></p>"
      },
      {
        "id": 9107,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">384 drugs</span></span></p>"
      },
      {
        "id": 9108,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">356 drugs</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As on 2022, total number of essential drugs approved by Government of India under NLEM is?</span></span></p>",
    "unique_key": "Q6396019",
    "question_audio": null,
    "question_video": null,
    "map_id": 34327,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. &nbsp;384 drugs</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>NEW National Lists of Essential Medicines (NLEM) 2022</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>384 Drugs</strong> included in NLEM 2022; <strong>34 new drugs added</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Criteria followed for inclusion in NLEM</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">be useful in diseases which is a <strong>public health problem in India</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">be <strong>licensed</strong>/approved Drugs Controller General (India) (DCGI)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">have <strong>proven efficacy</strong> and <strong>safety profile</strong> based on scientific evidence</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">be <strong>comparatively cost effective</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">be <strong>aligned</strong> with the <strong>current treatment guidelines</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">recommended under <strong>National Health Programs of India</strong>. (e.g. Ivermectin part of Accelerated Plan for Elimination of Lymphatic Filariasis 2018).</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">when <strong>more than one medicine are available</strong> from the <strong>same therapeutic class</strong>, <strong>one prototype</strong>/medically best suited medicine of that class to be included.</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>price of total treatment</strong> is considered and not the unit price of a medicine</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>fixed dose combinations</strong> are usually not included</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">vaccines as and when are included in Universal Immunization Program (e.g. Rotavirus vaccine).</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>384 Drugs </strong>included in<strong> NLEM 2022; 34 new drugs added</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: National List of Essential Medicines (NLEM), 2022</strong></span></span></p>",
    "correct_choice_id": 9107,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2282,
    "choices": [
      {
        "id": 9117,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">CDSCO control the quality of drugs imported into the country</span></span></p>"
      },
      {
        "id": 9118,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">States has no role in controlling drugs in state.</span></span></p>"
      },
      {
        "id": 9119,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Approval of new drugs proposed to be imported or manufactured in the country</span></span></p>"
      },
      {
        "id": 9120,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Central License Approving Authority in respect of whole human blood and its products, sera and vaccines and r-DNA products.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As a medical officer in a tertiary care hospital, you are part of a committee responsible for ensuring the safety, efficacy, and quality of drugs used within the institution. You are currently reviewing protocols for adherence to national standards in drug regulation. In this context, understanding the functions and scope of the Central Drug Standard Control Organization (CDSCO) is essential. Which of the following statements is NOT true regarding the Central Drug Standard Control Organization (CDSCO)?</span></span></p>",
    "unique_key": "Q2662732",
    "question_audio": null,
    "question_video": null,
    "map_id": 34329,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. States has no role in controlling drugs in states. </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>Central Drugs Standard Control Organization</strong> (CDSCO), in the <strong>Directorate of Director General of Health Services</strong>, along with <strong>Drug Control Organization</strong> in the <strong>States </strong>are responsible for <strong>safety, efficacy and quality of drugs</strong>, their <strong>import, manufacture, distribution, sale</strong> and standards.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>These are the main functions -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. Quality control of imported drugs <strong>(Option A)</strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2. Coordination of activities under State Drugs Control Authorities</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3. Approval for importation/manufacture of new drugs <strong>(Option C)</strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4. Laying standards for and act as &lsquo;Central Licensing Authority for blood and blood products, iv fluids, sera, vaccines, r-DNA products&rsquo; <strong>(Option D)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>QUALITY CONTROL IN DRUG SECTOR IN INDIA</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Quality control of drugs in India:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drugs and Cosmetics Act 1940</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drugs and Cosmetics Rules 1945</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Central Drugs Standard Control Organisation</strong> (CDSCO):&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Headed by:&nbsp;Central level: Drugs Controller General, India&nbsp;(DGHS, MOHFW)</span></span>\r\n\r\n\t<ul>\r\n\t\t<li style=\"list-style-type:none\">\r\n\t\t<ul style=\"list-style-type:square\">\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">State level: State Drugs Controllers</span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Zonal offices</strong>: Mumbai, Kolkata, Ghaziabad, Chennai.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Other Pointers -&nbsp;</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Two new drugs </strong>named <strong>Bedaquiline</strong> and <strong>Delamanid with anti-TB effect</strong> were approved for treatment of <strong>multidrug resistant TB</strong> by The <strong>Central Drugs Standard Control Organization</strong> (CDSCO)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> ed 551</strong></span></span></p>",
    "correct_choice_id": 9118,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 2288,
    "choices": [
      {
        "id": 9141,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Monoresistance</span></span></p>"
      },
      {
        "id": 9142,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Polydrug resistance</span></span></p>"
      },
      {
        "id": 9143,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Multidrug resistance</span></span></p>"
      },
      {
        "id": 9144,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Extensive drug resistance</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male patient presents with a cough, weight loss, and night sweats. He was previously treated for tuberculosis (TB) but has not shown improvement with standard first-line therapy. Sputum culture and sensitivity testing reveal resistance to both isoniazid and rifampicin. How should this patient&#39;s tuberculosis resistance profile be classified?&nbsp;&nbsp;&nbsp;&nbsp;</span></span></p>",
    "unique_key": "Q4238281",
    "question_audio": null,
    "question_video": null,
    "map_id": 34332,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans.&nbsp; C. Multidrug resistance</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Multidrug Resistant TB</strong> (MDR-TB): <strong>Resistance</strong> to <strong>Isoniazid and Rifampicin</strong>,&nbsp;with or without resistance to other drugs</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment of MDR</strong>-TB must be done on the <strong>basis of sensitivity testing</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Directly observed therapy certainly helps to improve outcomes and should be considered an integral part of the treatment of MDR-TB.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Monoresistance:</strong> Resistance to <strong>one first-line anti-TB drug only.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Polydrug Resistance:</strong> Resistance to <strong>more than one first-line anti-TB drug</strong>, other than both isoniazid and rifampicin</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Extensive Drug Resistant TB (XDR&ndash;TB):</strong> Resistance to <strong>rifampicin and isoniazid</strong> as well as to any <strong>member of the quinolone family</strong> and at least one of the following <strong>second-line TB treatments</strong>: <strong>kanamycin, capreomycin, or amikacin</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">XDR&ndash;TB is MDR TB with further resistance to 3 &ndash; 6 classes of second line drugs (older definition)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Principles of treatment for MDR-TB and for XDR-TB are same.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">XDR-TB does not transmit easily in healthy populations, yet is capable of causing &lsquo;epidemics in populations which are already stricken by HIV</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Multidrug Resistant TB</strong> (MDR-TB): <strong>Resistance</strong> to <strong>Isoniazid and Rifampicin</strong>&nbsp;with or without <strong>resistance to other drugs and&nbsp;Polydrug Resistance </strong>is&nbsp;<strong>resistance</strong> to more than <strong>one first-line anti-TB drug</strong>, other than both isoniazid and rifampicin</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 208)</strong></span></span></p>",
    "correct_choice_id": 9143,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  }
];
        let quizName = 'H. Programs, Schemes, Acts';
        let hierarchy = ["Cerebellum", "qBank", "PSM"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }
            
            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>